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Abstract
Introduction: Pulmonary air leaks from unhealed lung tissue are one of the most 
common complications after lung surgery. This adverse event leads to a delay in 
chest tube removal, prolonged pain, increased infections, prolonged hospital 
stay, and increased costs to the health care system. Objective: To define the 
most appropriate safe dose of dextrose 50% (D50) to seal air leaks in patients 
that have undergone lung resection surgery. Primary outcome was the 
occurrence of any adverse event. Methods: Prospective, single-arm, single-
center, rule-based escalation traditional 3+3 design phase I trial where patients 
with an active air leak on postoperative day #2 received intrapleural D50 at 
various dosage. Results: 12 patients were recruited. Increments of 50 mL, 100 
mL, 150 mL and 200 mL were tested. There was no severe adverse event. Air 
leak volume significantly decreased in the 24 hours following D50 administration 
compared to before (221 vs 31 L, p=0.013). Chest tube output remained similar 
(282 vs 365 mL, p=0.198). Transient non-significant increase of the glycemia was 
noted 1 hours after D50 (7.4 vs 10.0 mmol/L, p=0.156). 33% (4/12) were 
discharged home with a one-way valve. Pain level was not impacted by D50.
Conclusion: Hypertonic intrapleural glucose to treat air leaks after lung resection 
appears safe. The optimum dose is 150 mL. Its efficacy is promising and needs 
to be further studied prospectively.
Keywords
Prolonged air leak; dextrose; glucose; hypertonic; pleurodesis; intrapleural; post-
operative; lung resection
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Summary for Lay Audience
Lung resection surgery is frequently performed to remove lung cancer. 
Lung tissue is cut, and a drainage tube is left beside the lung at completion of the 
surgery to remove fluid that could accumulate around the lung. Air may also be 
leaking out of the lung, preventing the tube from being removed as the lung 
would collapse. Air leaks are also associated to infections around the lung, and
the longer the leakage persists, the higher the risk of infections. Air leaks prolong 
length of hospital stay, and therefore once a leak occurs efforts are made to seal 
it as soon as possible.
Several ways exist to stop those air leaks, including injecting a product in 
the chest through the existing tube to create inflammation around the lung. This 
process called pleurodesis has been performed using various agents, including 
talc. High concentration glucose (sugar) has emerged from reports as being a 
promising agent to achieve the same purpose, with less toxicity.
Before larger scale studies are performed, we aimed at assessing the 
safety of various dose of high concentration sugar. We enrolled 12 patients. No 
major side effects were linked to the injection of sugar in the chest. The air leak 
rate decreased dramatically. The pain level and fluid drainage did not change. 
The blood sugar temporarily rose without any meaningful consequence. 
Using this data, we can design a larger scale trial where we measure how
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1.1 BACKGROUND AND OVERVIEW
Air leaks from unhealed lung tissue are one of the most common complications 
following lung surgery including wedge resection, segmentectomy and 
lobectomy. Air leaks can lead to a delay in chest tube removal, prolonged pain, 
increased infections, prolonged hospital stay, and increased costs to the health 
care system1. Different agents have been used to seal air leaks by creating a 
pleurodesis (adhesions to obliterate the pleural space between the visceral and 
parietal pleura). They range from minerals (talc, our current standard) to cytotoxic 
agents (bleomycin). The success with each of these agents has been variable 
and come with the cost of complications that have restricted their use during the 
post-operative period2. Cross-contamination of talc with asbestos has been 
described in the past3 5, and although medical-grade talc is consider safe, some 
patients express concerns with its use in clinical practice. There has been recent 
interest in the use of 50% hypertonic glucose (D50) to create pleurodesis, with 
encouraging reports coming mostly from Asia6 8. We have performed a pilot 
study using 180 mL of D50 instilled through the chest tube for the management 
of post lobectomy air leak with encouraging results9, leading to reduced duration 
of air leak, chest drainage and hospital stay when compared to an historical 
cohort. This preliminary study used strict inclusion criteria of only lobectomy 
patients and excluded many other patients, such as patients with diabetes or any 
3
postoperative hyperglycemia that may benefit from this intervention. Also, the 
optimal dose of D50 was determined empirically and never clearly defined by 
previous work. It has been reported that high doses of D50 was associated to 
acute lung injury in some reports10. It is therefore critical that the optimal safe 
dose is clarified.
The objective of this work was to define the most appropriate safe dose of D50 to 
heal air leaks in patients that have undergone lung resection surgery (Phase I 
study).
We hypothesized that in patients with a post-operative air leak following lung 
resection, the bedside administration of D50 into the pleural space on post-
operative day 2 was safe (Phase I trial). This will provide the basis and data to 
proceed with a formal Phase II study to assess the effectiveness of the chosen 
dosage in reducing the duration of chest tube drainage, and then a Phase III 
randomized clinical trial against talc.
We anticipate that D50 will replace talc as our pleurodesis agent of choice and 
become the new standard not only for sealing air leaks following lung resection 
surgery, but also to achieve pleurodesis for chronic pleural effusions. Should we 
be successful in reducing post-operative air leaks in patients undergoing lung 
resections, we will reduce their hospital length of stay. This intervention should 
improve patient outcomes by shortening the duration that a chest tube is required
4
in the pleural space, reducing post chest tube removal pneumothoraces, 
decrease chest tube related pain, decrease the risk of post-operative infections, 
hospital length of stay, and health care costs. Should this simple, inexpensive, 
and novel therapy work to heal pulmonary air leaks, it will be a significant 
oracic 
Surgery.
In this thesis, dextrose 50%, glucose 50%, hypertonic glucose, hypertonic 





2.1 AIR LEAK AFTER LUNG SURGERY
Leakage of air after lung surgery is frequent. Lung surgery is performed for 
various indications. Resection of lung parenchyma for benign or malignant 
disease is routinely performed in tertiary health care institutions. Leakage of air 
after lung resection is one of the most frequent adverse events and is the most 
common cause of prolonged length of stay11. Data extracted from the European 
Society of Thoracic Surgeons database reported a rate of prolonged air leak 
(more than 5 days) of 9.9%12 after lobectomies or pneumonectomies. The 
Society of Thoracic Surgeon General Thoracic Surgery database reports a 
similar rate of prolonged air leak of 10.4%13 after lung resection. In a series of 
319 patients, Okereke and al.1 quantified that the prevalence of air leak after 
anatomic lobectomies was 58% immediately at the end of the surgery in the post-
anesthesia recovering unit. The median air leak duration was 3 days, but up to 
10% of patients were still leaking 7 days later. Our own experience during a
randomized controlled trial14 evaluated the role of autologous platelet rich plasma 
and concentrated platelet poor plasma on reducing air leak after lobectomies for 
cancer documented a 43.3% air leak prevalence at 4 days in the control group. A
recent a
institutional database showed that out of 866 patients who underwent a minimally 
invasive wedge or lobectomy from July 2012 to June 2017, at least 102 patients 
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(11.8%) suffered from a prolonged air leak (five days or more). Incidence of post-
operative air leak has been observed up to 15-26% in other single institution 
large series15,16. As the occurrence of adverse events of any grade leads to 
prolonged length of stay after lung cancer resection17, and that prolonged air 
leaks are directly associated to pulmonary complications (including empyema), 
readmissions and delayed hospital discharge18, it is important to find strategies to 
mitigate the impact of such adverse events.
2.2 PERSISTENT AIR LEAK IN THE SETTING OF SPONTANEOUS 
PNEUMOTHORAX
Air leaks not only arise post-operatively, but they can also occur spontaneously, 
giving rise to a pneumothorax. Pleurodesis and resolution of the leak are desired,
similar to patients with post-operative air leaks. Treatment usually includes 
simple drainage of the accumulated air via tube thoracostomy19 as recommended 
in the 2010 Guidelines of the British Thoracic Society. The annual incidence rate 
of primary and secondary spontaneous pneumothoraces is reported to be 22.7 
cases/100 000 people20 in an analysis of the France national database from 2008 
to 2011, with a subset that may require additional treatment than just simple 
drainage. The American College of Chest Physicians guidelines on spontaneous 
pneumothoraces published in 200121 recommended that patients with persistent 
air leaks (more than 4 days) should be evaluated for surgery to address the leak, 
followed by pleurodesis to reduce the recurrence rate. This is concordant with the 
8
British Thoracic Society 2010 guidelines19. Surgical treatment typically consists 
on finding the area of lung parenchyma leaking air and surgically remove it by 
stapling across normal lung tissue, in addition of performing a procedure that will 
promote pleurodesis post-operatively19,22. For non-operative candidates23,
chemical pleurodesis can be attempted. Other methods include keeping the tube 
with a one-way valve for a prolonged time hoping the leak will eventually stop 
and the use of endobronchial devices or drugs. Methods applied to promote 
pleurodesis in the post-operative setting should also be effective in this 
population.
2.3 MONITORING OF AIR LEAK
Lung resection almost always requires one or more drainage tube(s) left in the 
pleural cavity to collect the excess of fluid and air that could accumulate around 
the lung. Such accumulation can lead to catastrophic physiological 
consequences for the patient, culminating to cardiorespiratory arrest if a tension 
pneumothorax develops or if bleeding is unrecognized for instance. This tube 
needs to be connected to a chest drainage system to monitor the amount and 
quantity of fluid, and also to prevent reflux of air from the outside world back into 
the chest as the pleural cavity is a negative pressure environment compared to 
the atmospheric pressure. 
9
Chest drainage systems can be classified as either analog or digital. Analog 
drainage systems are modifications of the three-bottle chest drainage system24.
They rely on the visual evaluation of the presence of air bubbles in the water 
chamber by an observer who then reports it in the patient chart typically using a 
standardized classification22,25 27. These systems are relatively inexpensive but
are cumbersome for patients as the device is relatively large, and subjective. In 
addition, if suction is required, the analog device has to be connected to the 
systems, digital pleural drainage systems are a newer technology that have been 
shown to improve interobserver reliability in the assessment of pulmonary air 
leak28, as the objectivity is increased. Additional advantage by design includes 
recording of the air leak over time and better ambulation for patient as the suction 
is battery powered. Gilbert performed a randomized controlled trial29 of digital 
versus analog pleural drainage systems after lung resection in which the digital 
system reduced the number of chest tube clamping trials. Using specific air leak 
flow thresholds for chest tube removal on the digital system, no patients had 
chest tube reinsertion for worsening pneumothorax or subcutaneous 
emphysema. These digital devices are being incorporated more and more 
included in post-operative clinical pathways30. A recent meta-analysis including 
10 randomized controlled trials enrolling 1268 patients showed that digital 
systems statistically reduced the duration of chest tube placement, the length of 
hospital stay, the air leak duration, and postoperative costs31. They are now 
10
2.4 PLEURODESIS
2.4.1 DEFINITIONS AND INDICATIONS
Pleurodesis is defined by Hallifax et al. as the permanent apposition of the 
32. Inflammation within the 
pleural cavity is voluntarily created to generate adhesions and pleural symphysis. 
It is categorized as chemical when the mechanism involves the administration of 
an agent within the pleural space, or surgical when the parietal pleura is 
surgically excised (pleurectomy) or damaged (pleural abrasion). The aim in both 
cases is to prevent future collapse of the lung caused by either air or fluid.
Several indications exist to perform pleurodesis. Prevention of recurrent 
spontaneous pneumothoraces and treatment of an active air leak in non-surgical 
candidates are the main indications32. Malignant pleural effusions may also be 
treated by chemical pleurodesis33. Benign effusion such as chylothorax have also 
been treated by performing chemical pleurodesis34 36.
2.4.2 AGENTS USED TO ACHIEVE CHEMICAL PLEURODESIS
All the sclerosing agents possess the same attribute: damaging pleural 
mesothelial cells to trigger an inflammatory cascade where a neutrophilic 
exudate is formed. Multiple factors come at play including the ability of fibroblasts 
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and mesothelial cells to produce collagen, and an equilibrium between 
metalloproteinases and plasminogen activators37. Certain anti-inflammatory 
agents such as steroids and diclofenac reduce the degree of pleurodesis in 
experimental studies38,39, while others (cyclooxygenase-2 inhibitors) do not37.
Several agents exist. In a recent systematic review32 assessing the effectiveness 
of chemical pleurodesis in spontaneous pneumothoraces recurrence prevention 
and in a Cochrane meta-analysis33 on interventions for the management of 
malignant pleural effusions, the following agents were listed to induce 
pleurodesis:





silver nitrate (antiseptic agent)













OK-432 (inactivated preparation of Streptococcus pyogenes, very popular 
in Japan6)
They all have various risk of toxicity, and a simpler agent such as dextrose could 
possibly provide similar efficacy with a better safety profile. For example, C. 
parvum and mepacrine are known to induce fever more frequently than other 
agents. Blood may be difficult to collect and inject, and may clog the chest tube. 
Mepacrine, mitoxantrone and C. parvum are associated with pain33. Patients may 
be allergic to some of these agents.
While not listed in the above-mentioned reviews, administration of hypertonic 
glucose in the pleural cavity has been described to obtain pleurodesis (cf below), 
and its first documented use to as a chemical pleurodesis agent was in 1906 by 
Spengler40, and first success in 192341,42.
2.5 HYPERTONIC GLUCOSE TO ACHIEVE PLEURODESIS SUMMARY 
OF ALL DATA AND SYSTEMATIC REVIEW
13
The systematic review was conducted in accordance to the Preferred Reporting 
Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines43 (Table 
1). The search was completed on December 9, 2019 and updated on January 3, 
2020. The search strategy is located in Appendix M. 
Articles where the intervention was intrapleural administration of any volume of 
hypertonic glucose (Intervention) on human patients (Population) were included. 
The objective of the search was to find data on the safety (Outcome) of 
intrapleural hypertonic glucose to induce pleurodesis. It was mandatory for the 
article to include the population size, and information on adverse events.
Exclusion criteria consisted of non-human or pediatric populations, non-English 
abstracts and/or articles and review articles.
Two authors (M Qiabi, A Ednie) extracted the data from the eligible studies and 
cross-checked the results subsequently. There was 100% agreement in the 
results. Variables that were extracted included: general study characteristics 
(author, year, study design, location, number of patients), patient population, 
intervention and occurrence of adverse events.
A total of 98 entries were found after performing the PubMed search. After 
articles6 8,10,34,35,44 50 were kept for the review.
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title, abstract, and sometimes the article itself, one9 additional article was added 
to the review.
SCOPUS search yielded 7 results, none of which were either relevant or new 
addition compared to the other two databases.
Cochrane search yielded 9 results, none of which were either relevant or new 
addition compared to the other three databases.
Finally, Web of Science search yielded 88 results, three36,51,52 of which were new 
additions compared to the other four databases.
After reading each article and reviewing the references, 642,53 57 additional 
articles have been added to the list. A total of 23 articles were therefore 
reviewed, covering 447 patients (Table 1). The Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) flow diagram (Figure 1) and 
the PRISMA Checklist (Table 2) are attached. The volume of intrapleural 
dextrose during initial administration ranged from 30 mL to 500 mL. The maximal 
total volume administered was 1500 mL (3 times 500 mL over 3 days).
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2.5.1 INDICATIONS
Administration of hypertonic glucose into the pleural cavity was performed for the 
following indications:
spontaneous pneumothorax (17 studies6 8,10,42,44 50,53,54,56,57,  313 patients)
prolonged air leak after lung resection (5 studies6,9,52,54,55, 70 patients)
chylothorax (3 studies34 36, 42 patients)
malignant pleural effusion (2 studies51,54, 22 patients)
2.5.2 KNOWN POTENTIAL RISKS
In five papers6,9,52,54,55, the population studied were post-lung resection patients 
with air leak (70 patients). In these 70 subjects, reported adverse events were as 
follow:
mild transient hyperglycemia (n=26/70)
mild transient chest pain
mild transient fever
mild increase in chest tube output
In these 70 patients, reported adverse events were mild. This population is 
similar to the population we plan to study. The concentration of dextrose was 
50%. Except for one study55 in which the data was not available, they all had 
administration of 200 mL, repeated up to 2 other times for a total of 600 mL over 
16
3 days. There was no infectious complication in this population with air leak after 
lung resection.
In the whole population (447 patients) comprising all indications for pleurodesis,
infectious complications related to the intervention were rare. One study7 where 
20 patients had spontaneous pneumothoraces and were treated with bullectomy, 
mechanical abrasion and administration of 500 mL of Dextrose 50% in the 
operating room 
8
where 13 patients had spontaneous pneumothorax treated with a chest tube and 
then administration of between 200 to 500 mL of dextrose 50%, repeated up to a 
total of 3 times (500 mL administered 3 times over 3 days) reported 2 patients 
prolonged period of time (25 and 35 days), and they both had repeated 
administration of 500 mL of dextrose 50% (one had a total of 2 doses and the 
other 3 doses). All these 3 patients were treated conservatively with antibiotics.
Ischemic colitis induced by dehydration was reported after the administration of 
400 mL of Dextrose 50% on a 97 years old patient to induce pleurodesis after a 
spontaneous pneumothorax53. This was treated conservatively with rehydration 
and surgery was not required.
17
Chee44 reported a case of dextrose pneumonitis. The 51 years old male with 
chronic obstructive airways disease complicated by cor pulmonale and 
hypercapnic respiratory failure had a spontaneous pneumothorax. He had a 
prolonged air leak for 41 days. Intrapleural instillation of 50 mL of Dextrose 50% 
was performed and the patient experienced cardiorespiratory collapse requiring 
cardiopulmonary resuscitation. It was noted that a copious quantity of secretions
was coming from the endotracheal tube, positive for glucose by a dipstick. The 
patient recovered well after that event and the leak stopped. It was postulated 
that osmotic pulmonary edema may have been caused by the high tonicity of the 
dextrose 50%.
Of the 447 patients who underwent intrapleural hypertonic dextrose 
administration for pleurodesis, a total of 3 deaths were reported.
1- In Tsukioka7 paper, a 79 years old male with severe emphysema, 
unresectable lung cancer who recently had chemotherapy, underwent a 
bullectomy, mechanical abrasion of the pleura, and administration of 500 
mL of dextrose 50% in the pleural cavity. Twenty-four days after his 
surgery, he passed away from a pneumonia. It is unclear whether his 
death is related to the administration of a sclerosing agent.
2- In Hamada10 paper, a 72 years old male with a stage IV lung cancer and 
severe emphysema, presented with spontaneous pneumothorax. He was 
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first treated with 5 rounds of OK-432 (sclerosing agent available in Japan 
to induce pleurodesis), but it did not work, and the leak was still present. 
Then, 4 rounds of autologous blood and 200 mg of minocycline were 
injected into the pleural cavity via the chest tube, again without success. 
Finally, 200 mL of dextrose 50% was injected into the pleural space. The 
patient suffered from acute respiratory distress syndrome and had to be 
intubated. He eventually died from progression of respiratory failure. While 
there seems to be a temporal association, the causality is uncertain.
3- In Hamada10 paper, a 84 years old male with idiopathic pulmonary fibrosis, 
on home oxygen and hypercapnic respiratory failure developed a 
spontaneous pneumothorax. A chest tube was inserted, and 400 mL of 
dextrose 50% administered into the pleural space. Immediate pain and 
respiratory failure occurred. It was recommended for the patient to be 
intubated, but the family refused. The patient died 1 week later from 
progression of respiratory failure.
In the case of Patient 1, the death seems to be related to a nosocomial 
pneumonia and not from the intervention. Patient 2 had multiple attempts at 
pleurodesis with various agents (OK-432, blood, minocycline) before dextrose 
was tried. This is not the type of intervention planned in the current proposed 
study. Patient 3 seemed to have an acute reaction to dextrose 50%. The volume 
administered is twice the maximum dose we are planning to use.
19
In summary, after reviewing the current literature, the most common and 






It is hypothesized that the value of the information gained by performing this 
study will allow health care providers to have another option when comes the 
time to offer a patient chemical pleurodesis (instead of offering talc), thoracic 
surgeons or respirologists will have the option of administering hypertonic 
glucose. Talc is associated to acute toxicities like the Acute Respiratory Distress 
Syndrome58, and healthcare workers with occupational exposure to talc may be 
at higher risk of developing lung cancer59. Of note, the risk of reporting bias 
exists, as papers with severe adverse events may not have been published. On 
an individual study level, most of these studies were retrospective, with all the 
biases associated with this design (selection).
2.5.3 KNOWN POTENTIAL BENEFITS
After pulmonary resection, air leak is one of the most common complications 
arising from lung parenchyma at sites of division of adhesions, fissure dissection 
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or lung retraction for exposure. A chest tube inserted at the end of the procedure 
will drain any ongoing air-leak allowing the underlying lung to re-expand. 
Patients who have an air leak on post-operative day 2 typically are offered 
observation, hoping the air leak will seal by itself. However, previous work 
showed that a significant number of patients who still leak on POD2 will have a 
prolonged air leak (more than 5 days), and then will be typically offered one of 3 
options: 
1- waiting a longer period of time before removing the chest tube, with possibly 
discharging the patient home with a small one-way valve if the lung stays well 
inflated, hoping the leak will have stopped at the next outpatient visit
2- injection of a sclerosing agent (such as talc) into the pleural space hoping the 
leak will stop
3- reoperation, hoping to stop the leak 
It is known in the thoracic surgery literature that the longer a leak persists, the 
more likely the patient may suffer from an infection of the pleural space
(empyema)60,61. Other complications such as catheter-related discomfort, 
arrhythmia or deep vein thrombosis could potentially be attributed to prolonged 
length of stay.
Most reports from Table 1 have shown some efficacy in inducing pleurodesis and 
achieving the desired outcome. We postulate that participants to the study will 
therefore potentially be able to be discharged home sooner, have their chest tube 
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removed sooner (leading to pain relief), and because the leak would stop earlier, 
there is a hypothetic benefit in reducing the risk of post-operative infectious 
complications18.
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Table 1 - List of all studies. VATS: video-assisted thoracic surgery, POD: post-operative day. a,b,c cf description of the events in the text
Author Year Study design Location n Population Intervention Adverse events
Chen34 2010 Retrospective 
case series
China 5 post-esophagectomy chylothorax 50% glucose + 0.1% lidocaine (volume?) through 
the tube
self-resolving dyspnea
Chung49 2008 Prospective 
cohort
South Korea 49 primary spontaneous pneumothorax thoracoscopic procedure (bleb 
resection/bullectomy/electrocoagulation) + 
instillation of dextrose 20% 200 cc
rate of fever 22% (dextrose group) vs 10% (no 
dextrose group)
Tsukioka7 2013 Retrospective 
cohort
Japan 20 secondary spontaneous pneumothorax VATS bullectomy + mechanical abrasion + 
dextrose 50% (500 cc)
1 deatha 24 days after the surgery from a 
pneumonia,1 prolonged air leak (15 days), 2 
Hamada10 2017 Retrospective 
case series
Japan 2 spontaneous pneumothorax 1- 200 mL of dextrose 50%
2- 400 mL of dextrose 50%
2 deathsb
Peng50 2002 cohort China 45 recurrent pneumothorax 60-80 mL of Dextrose 50% through the tube 7/45 had mild pain
Chee44 1992 Retrospective
case report
Singapore 1 spontaneous pneumothorax 50 mL dextrose 50% pulmonary edemac
Fujino6 2016 Retrospective 
cohort
Japan 46 35 post-lung resection patients with air 
leak and 11 patients with pneumothorax 
and prolonged air leak with a tube in place
200 mL of 50% glucose, between 1 and 3 doses, 
7 patients had OK-432 after their 3rd dose for 
failure of the glucose to work
mild transient hyperglycemia in 20/46 patients
Takanashi53 2015 Retrospective 
case report
Japan 1 spontaneous pneumothorax 50% glucose, 400 mL ischemic colitis secondary to severe 
dehydratation (1960 mL/4 hours), prerenal acute 
renal failure
Togo54 2016 Retrospective 
cohort
Japan 29 14 pneumothorax, 11 post-lung resection 
air leak, 4 malignant pleural effusion
200 mL of 50% glucose (2 patients had 100 mL 
for « poor performance status »)
Mild transient hyperglycemia, chest pain and 
fever
Tsukioka8 2013 Retrospective 
cohort
Japan 13 spontaneous pneumothorax 200 - 500 mL 50% glucose through the tube, they 
often required more than one treatment
2 "bacterial pleuritis" (both of them required more 
than 1 treatment, and they had their tube 25 and 
35 days, treated with antibiotics only), 1 aspiration 
pneumonia
Albargawi9 2016 Prospective 
cohort
Canada 10 post-lobectomy air leak 200 mL dextrose 50% with lidocaine, once or 
twice
mild increase in chest tube output, mild increase 
in blood sugar
Frick45 1990 Cohort Germany 32 spontaneous pneumothorax thoracoscopic pleurodesis with electrocoagulation 
of bullae, visceral/parietal pleurae cauterized, 
chemical pleurodesis with dextrose 50%
Horner syndrome (secondary to pleural 
cauterization)
Sumitomo52 2017 Cohort Japan 13 post-lung resection air leak 200 mL glucose 50%, repeated as needed (2 
patients had pleurodesis twice)
none
Kitagata55 2018 case report Japan 1 Air leak post right lower lobectomy glucose 50% none
Yaginuma56 2016 case report Japan 1 spontaneous pneumothorax on 
mechanical ventilation
pleurodesis with glucose 50% and minocycline none
Kajikawa57 2017 case series Japan 5 spontaneous pneumothorax pleurodesis with 200 mL glucose 50% transient hyperglycemia
Hennell42 1939 case report US 2 Chronic pneumothorax glucose 50% 50 mL, then 60% 67 mL none
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Table 1 - List of all studies (continued). VATS: video-assisted thoracic surgery, POD: post-operative day. a,b,c cf description of the events in the text
Author Year Study design Location n Population Intervention Adverse events
Lai35 2019 Prospective 
cohort
China 34 Chylothorax post-esophagectomy (30), 
lobectomy (2) and mediastinal mass 
resection (2)
daily 50% dextrose 100 mL (IL-2 if diabetic) Electrolytes imbalances attributed to chyle 
leak. No pleural infection
Tsuboshima47 2018 Retrospective 
cohort
Japan 106 Spontaneous pneumothorax Bullectomy + 50 mL 50% glucose solution for 
pleural coating on an absorbable sheet 
No empyema in the glucose group, mild 
increase in pain score (3 vs 2), marginal 
increase in chest tube output. No 
dehydratation, no long-term restrictive 
physiology on pulmonary function tests
Yamane48 2014 Case report Japan 1 Spontaneous pneumothorax 50% glucose None
Van den 
Brande46
1989 RCT Belgium 10 Spontaneous pneumothorax 30 mL of 30% glucose + 250 mg of 
oxytetracycline
None (no fever, no pleural effusion)
Li36 2011 Case series China 3 Chylothorax post-pulmonary resection 50% glucose None reported
Khanna51 2010 Retrospective 
cohort
Great Britain 18 Malignant pleural effusion Talc slurry in dextrose 50% solution None reported
24
Figure 1 - PRISMA 2009 Flow Diagram
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Additional records identified 
through other sources 
(n = 9) 
Records after duplicates removed 
(n = 1129) 
Records screened 
(n = 1129) 
Records excluded 
(n = 1007) 
Full-text articles assessed 
for eligibility 
(n = 122) 
Full-text articles excluded (n = 99) 
- Wrong/no intervention (n = 80) 
- Review article (n = 10) 
- Missing data (n = 6) 
- # unknown (n = 2) 
- Duplicate population (n = 1)   
Studies included in 
qualitative synthesis 
(n = 23) 
Table 2 - PRISMA 2009 Checklist
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Section/topic # Checklist item 
Reported 
on page # 
TITLE 
Title 1 Identify the report as a systematic review, meta-analysis, or both. 12
ABSTRACT 
Structured summary 2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number. 
12-13
INTRODUCTION 
Rationale 3 Describe the rationale for the review in the context of what is already known. 6-12
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS). 
13
METHODS 
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number. 
n/a
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale. 
13
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched. 
13-14




Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis). 
13
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators. 
n/a
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made. 
n/a
Risk of bias in individual 
studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis. 
n/a
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). 13
Table 2 - PRISMA 2009 Checklist
26
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis. 
n/a
Section/topic # Checklist item Reported 
on page # 
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies). 
n/a
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified. 
n/a
RESULTS 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions 
at each stage, ideally with a flow diagram. 
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Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations. 
22-23
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). n/a
Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. 
22-23
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. n/a
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). n/a
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). n/a
DISCUSSION 
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers). 
15-19
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias). 
n/a
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research. 15-19
FUNDING 
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for 





3     RATIONALE, RESEARCH QUESTION, OBJECTIVE AND HYPOTHESIS
Air leaks from unhealed lung tissue are one of the most common complications 
after lung surgery including wedge resection, segmentectomy and lobectomy. Air 
leaks can lead to a delay in chest tube removal, prolonged pain, increased 
infections, prolonged hospital stay, and increased costs to the health care 
system1. Different agents have been used to heal air leaks by creating a 
pleurodesis (adhesions to obliterate the pleural space between the visceral and 
parietal pleura). The success with these agents has been variable and come with 
the cost of complications that have restricted their use the post-operative period2.
There has been recent interest in the use of D50 to create pleurodesis with 
encouraging reports coming mostly from Asia6 8. We have performed a pilot 
study using D50 instilled through the chest tube for the management of post 
lobectomy air leak with encouraging results9. This preliminary study used strict 
inclusion criteria of only lobectomy patients and excluded many other patients 
such as patients with diabetes or any postoperative hyperglycemia that may 
benefit from this intervention. Also, the optimal dose of D50 was chosen 
empirically and never clearly defined by previous work. It has been reported that 
high doses of D50 was associated to acute lung injury10. It is therefore critical 
that the optimal safe dose is clarified. A phase I study was therefore designed.
Research question: Is intrapleural dextrose 50% administered 2 days after lung 
resection safe when an air leak is present?
Objective: To confirm safety of various dosage of D50 to heal air leaks in 
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patients that have undergone lung resection surgery (Phase I study).
Hypothesis: In patients with a postoperative air leak following lung resection, the 
bedside administration of D50 into the pleural space on postoperative day 2 is
safe (absence of severe adverse events related to D50).
We predicted that D50 would be found safe because no severe adverse events 
occurred with optimum dose (dose providing the best efficacy for the most 
acceptable toxicity) found in this Phase I study. Results provide the motivation 
and data to proceed with a formal Phase II study to assess the effectiveness of 
the chosen dosage in reducing the duration of chest tube drainage, and then a 




4     METHODS
A detailed protocol (Appendix F, protocol MQRM711 v2.05) has been submitted 
to the Health Canada Therapeutic Products Directorate which issued a No 
Objection Letter (Appendix E) following evaluation of our Clinical Trial Application 
(CTA, control number 229051). The protocol was elaborated using the National 
Institutes of Health (NIH) protocol templates for clinical trials62. Training in Part C, 
Division 5 of the Food and Drug Regulations was completed by the investigating 
team as part of a Health Canada requirement for the investigation of drugs in 
regulated clinical trials involving human subjects. 
The protocol (Appendix F) outlines the background information and scientific 
rationale, objectives and purpose, study design and endpoints, study enrollment 
and withdrawal, study agent, study procedures and schedule, assessment of 
safety, clinical monitoring, statistical considerations, source documents and 
access to source data/documents, quality assurance and quality control, 
ethics/protection of human subjects, data handling and record keeping, study 
administration, conflict of interest policy, and literature references. This CTA was 
requested by the Western University Health Sciences Research Ethics Board 
(HSREB) after Full Board review. The study was subsequently approved by 
Western University HSREB (#113906) and Lawson Health Research Institute (R-
20-071). The trial is registered at ClinicalTrials.gov (NCT03905408).
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This trial took place at London Health Sciences Centre (LHSC) Victoria 
Hospital, London, Ontario, on the Thoracic Surgery ward (C5-300).
Below is a summary of the protocol.
4.1 DESCRIPTION OF THE STUDY DESIGN
In this prospective single-arm, phase I, single-center trial, patients with air leak 
on postoperative day 2 following lung surgery were invited to participate in the 
study. The precise definition of air leak is found in section 4.5. The solution to be 
used as pleurodesis agent consisted of sterile 50% glucose injected in the chest 
tube, followed by the administration of 20 mL of 1% lidocaine to flush the tube 
and ensuring the glucose is in the pleural space, and to provide some local 
anesthesia to the parietal pleura.
Twenty-four hours after the intervention, if there is air leak cessation (defined 
below), chest tube removal was considered by the surgical team. If an air leak 
was still present, no further intervention was planned. The volume of D50 
administered was incremental and followed a rule-based escalation, traditional
3+3 design63 (Figure 2): 3 patients had a set dose, and if there were no dose-
limiting toxicities (Appendix H) or less than 2 moderate toxicities, the next group 
of 3 patients went up one increment following review from the Data and Safety 
Monitoring Board. In addition, each patient was reviewed on a weekly basis by 
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the surgical team to ensure concordance in adverse events (if any) noted. The 
empiric increments were 50 mL, 100 mL, 150 mL, and 200 mL. A maximum of 12 
patients were to be enrolled.
Figure 2 Traditional 3+3 design (left plot). From Le Tourneau et al.63 SD =
starting dose; DLT = dose-limiting toxicity; RD = recommended dose. This phase 
I trial use the thresholds displayed in the right plot.
The 3+3 design was selected as it is commonly used in Phase I drug trials
(notably in oncology) and uses a progressive approach (rule-based) to find the 
appropriate dose for further trials or therapeutic uses. The only assumptions are 
that the drug of interest has both a dose-efficacy and a dose-toxicity curve. Once 
prespecified dose-limiting toxicities are experienced by at least 2 patients, the 
escalation stops, and the dose recommended for phase II trials would typically be 
the increment just below the one that triggered the toxicities. An issue that can 
arise is that titration can be slow, potentially preventing many patients from 
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receiving drugs of effective dosage (subtherapeutic) while only very few will 
actually receive trialled drugs near the recommended dosage used for phase II 
trials. Most trials using this design will have 6 or more thresholds63. In our case, 
the first increment (50 mL) corresponds to the lower end of the range of volumes 
administered to patients in the systematic review. Each dextrose 50% syringe 
comes in 50 mL volumes; therefore, increments were arbitrarily chosen to be 50 
mL throughout this study and that is why the suggested modified Fibonacci 
sequence (smaller dose increments as the dose increases) was not followed.
Finally, the highest threshold used was 200 mL as it is one of the commonest 
volumes administered in the systematic review. At a volume of 200 mL and
above, some patients seem to experience adverse events, and therefore we 
elected not to go higher.
Several variations of the 3+3 design exist, with different rules or accelerated 
escalation designs (based on plasma drug concentration for example). The main 
advantage of this traditional design is that it is safe, simple to implement and has 
a proven track record, being in use for many decades in large studies leading to 
drug approval by organizations such the U.S. Food and Drug Administration.
Model-
real-time to establish how quickly the dose can be escalated to reach the phase 
II dose quicker. Biostatistical expertise is mandatory. Several assumptions on the 
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dose-toxicity curve have to be made beforehand and, if wrong, may fail to reach 
the recommended dose for the phase II trial.
For all the aforementioned reasons, the traditional 3+3 design was selected in 
the current study.
4.2 DATA AND SAFETY MONITORING BOARD (DSMB)
As mandated by Health Canada, a DSMB was constituted. Four physicians 
expert in their field and consultants at LHSC were recruited:
Dr. Richard Inculet, Thoracic Surgery
Dr. Nathan Ludwig, Anesthesia & Perioperative Medicine
Dr. Amanda Berberich, Endocrinology and Metabolism
Dr. Michael Mitchell, Respirology
These individuals were selected for their knowledge in the pulmonary physiology, 
the post-operative course after lung resection, the impact of dextrose when 
administered in high concentration, the treatment of hyperglycemia and the 
treatment of pain. Members of the DSMB have signed a declaration confirming 
the absence of any financial or other interest with any of the investigators or 
other organizations involved in the study that could represent a potential 
perceived or true conflict of interest.
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Communications between the DSMB and the investigators were by secured
email. The DSMB reviewed data from REDCap (secure, web-based, institution-
approved software), along with a narrative of the 3 patients in each threshold to 
confirm moving up to the next increment.
The DSMB operated using strict and well-defined halting rules (Appendix H).
4.3 PRIMARY ENDPOINT
The primary outcome of this Phase I study is the safety of intrapleural dextrose 
50% as defined by the lack of grade 3, 4 or 5 adverse event at any given D50 
volume according to the Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.064. Each adverse event has its own criteria to define the 
grade of the adverse event (AE). Grade 1 is considered a mild AE, while grade 5 
is an AE resulting in death. 
The AE were collected by the investigators and transmitted to the DSMB with a 
detailed narrative of the AE. Questions from the DSMB were answered. The 




Presence of any adverse event
Persistence (yes/no) of air leak 24, 48 and 72 hours post dextrose
administration, and change in the air leak rate
Pain score at baseline, 1 hour, 3 hours, 6 hours, and 24 hours after
dextrose administration (visual analog scale)
Point-of-care glucose measurement at baseline, 1 hour, 3 hours, 6 hours,
24 hours after dextrose administration
Chest tube output during the first 24 hours after dextrose administration
Length of hospital stay
Duration of chest tube drainage
Need to discharge the patient home with a one-way (Heimlich) valve




Need for any intervention to treat hyperglycemia
Recurrence of air leak
Demographic characteristics (age, gender, smoking status, comorbidities, 
diagnosis, type of surgery, surgical approach and the air leak rate pre-D50) were 
also collected. The Charlson Comorbidity Index (CCI)65 is a prognostic score 
derived from 19 pre-defined comorbid conditions. Each condition has a different 
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weight based on the association with 1-year mortality. It is calculated for each 
patient.
4.5 AIR LEAK DEFINITION
For
follow using the Medela ThopazTM digital system (Figure 3 and 4):
- Air leak
o Air leak equal or more than 40 mL/min for at least 1 hour during the 
last 12 hours if the tube is on suction, or
o Air leak equal of more than 20 mL/min for at least 1 hour during the 
last 12 hours if the tube is on gravity mode
- Cessation of air leak
o No record of sustained air leak (1 hour or more) of 40 mL/min or 
more for the last 12 hours if the tube is on suction, or
o No record of sustained air leak (1 hour or more) of 20 mL/min or 
more for the last 12 hours if the tube is on gravity mode
This definition is based on Gilbert et al. paper29 which used those criteria in a 
randomized controlled trial to decide when to remove chest tubes. Using those 
criteria, no chest tube reinsertions for worsening pneumothorax or subcutaneous 
emphysema after chest tube removal occurred.
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Figure 3 Digital drainage system, Medela ThopazTM. There is a sample 
port where a needle can be inserted, obviating direct trauma to the chest 
tube. Reproduced after obtaining authorization from Medela Canada, Inc.
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Figure 4 Digital drainage system, Medela ThopazTM. A graph displays the 
leak rate over the last 24 hours. Reproduced after obtaining authorization from 
Medela Canada, Inc.
4.6 INCLUSION CRITERIA
In order to be eligible to participate in this study, an individual must meet all of 
the following criteria:
1. 18 years old or older
2. Lung resection is a wedge, segmentectomy, lobectomy or bilobectomy
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3. Surgery was not performed to induce pleurodesis (no pleural abrasion, no
pleurectomy, no talc)
4. Procedure performed by video-assisted thoracic surgery, or by
thoracotomy
5. Presence of an air leak on the digital draining system on POD#2
Patients who did receive talc as part of their surgery were not invited in this 
study, as the effect of concomitant talc plus hypertonic glucose is unknown, and 
this was not the purpose of the current trial.
4.7 EXCLUSION CRITERIA
An individual who meets any of the following criteria was excluded from 
participation in this study:
1. Large air leak arbitrarily defined as more than 1,000 mL/min
2. Allergy to local anesthetics
3. Hemodynamic instability
4. Untreated coronary artery disease
5. Need for mechanical respiratory support
6. Any other early post-operative complication
7. Immunity disorder
8. Large fluid output arbitrarily defined as over 500 mL in the last 12 hours
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9. Inability to give consent
10.Fasting glucose 14 mmol/L the morning of the intervention (arbitrarily
chosen cut-
controlled)
11.Endocrinology service not available to co-manage patients with either
diabetes, or a fasting blood glucose 7 mmol/L, or HbA1c > 6.5%
12.Postoperative evidence of an active thoracic (lung or pleura) infection with
systemic inflammatory response syndrome (SIRS) (2 or more of
temperature > 38, heart rate > 90, respiratory rate > 20, WBC > 12)
Patients had to be competent to participate to this study, proxy consents were 
not allowed. There is a theoretical risk of increased myocardial demand when 
pleurodesis is performed due to the inflammatory reaction created, therefore 
patients with untreated coronary artery disease were excluded. One concern 
raised by Health Canada was the risk of infectious complications, and it was 
decided to exclude patients with immunity disorders for this reason. 
The last 3 criteria were added after review by Health Canada which was 
particularly concerned by the risk of severe hyperglycemia and the effect on 
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4.8 STUDY AGENT AND METHOD OF ADMINISTRATION
The glucose solution is manufactured by Hospira, company owned by Pfizer Inc.
00037974). The agent comes in pre-filled 50 mL syringes (AnsyrTM or 
LifeShieldTM). It was not possible to use the AnsyrTM II system due to national 
shortage in 2019-2020. An equivalent delivery system (LifeShieldTM, product 
number 04902L50) was therefore used (Lot 04-431-DK, expiry 20210401). Each 
syringe was acquired from LHSC pharmacy at a $30.38 CAD unit cost. Thirty-six 
syringes were acquired from funds granted by Western University Department of 
Surgery (Appendix A). These syringes were stored on room temperature until 
their utilization as recommended in the product brochure (Appendix I).
This agent was administered by a single individual (MQ) involved in this study in 
a standardized approach. The digital draining system was turned off and hanged 
over an intravenous pole, so it sta
one meter. The chest tube was not clamped to avoid creation of a tension 
pneumothorax. The patient is placed on a contralateral lateral decubitus position 
to facilitate entry of the glucose solution in the pleural space by gravity. The hub 
of the digital drain was sterilized with alcohol swabs. Administration of the 
solution was performed on a sterile fashion. Lidocaine 1% 20 mL was then 
injected to provide topical anesthesia to parietal pleura and to flush the excess of 
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hypertonic glucose from the chest tube. The patient was then asked to move 
every 15 minutes from one side to another. After 2 hours, the digital system was 
placed again on the ground and suction was applied (-20 cm H2O).
4.9 STATISTICAL ANALYSES
Paired t-test is used to compare paired, continuous variables (volume of air 
leaked, chest tube output) after ensuring normality of the distribution of the 
differences using the Shapiro-Wilk test. Repeated-measures ANOVA is used to 
analyze glycemia data over various time period. Intention to treat analyses are 
performed. A p-value of 0.05 or less is considered statistically significant.
Post-lung resection air leak tends to naturally decrease over time as the leak 
seals spontaneously. Comparing the volume of air leaked before and after an 
intervention without accounting for that previously stated fact could generate 
misleading results. Interrupted time series analysis/segmented regressions can 
be used when an outcome variable is measured over time, before and after an 
intervention. This quasi-experimental design is typically used in population-based 
studies, notably by governments to determine if a policy is effective66 71. A 
-
-D50. Both the immediate impact on the air leak rate right 
after D50 (seen in a change in the intercept of the regression line in the model 
post-D50) and the impact on the change of air leak rate over time (slope) can be 
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assessed. This can statistically confirm the impression of efficacy seen on 
several patients (Figure 5). A statistical decline in the intercept post-D50 is 
clinically interesting and a desired effect (immediate air leak decrease after D50 
administration). It is more difficult to interpret the slope it can become less 
negative (closer to 0) after D50 and this would not necessarily mean D50 is 
detrimental for the air leak. Therefore, only the immediate impact of D50 
(intercept) is analyzed. The R code is found in Appendix L and is adapted from 
Professors Haider and Law work72.
SPSS version 26 (IBM Corp. Released 2019. IBM SPSS Statistics for Macintosh, 
Version 26.0. Armonk, NY: IBM Corp.), R version 4.0.3 (R Core Team (2020))73







From March 12, 2020 to December 24, 2020, 176 consecutive patients were 
screened for eligibility. The procedures performed were as follow:
- 83 wedge resections
- 78 anatomical lobectomies
- 13 segmentectomies
- 1 bi-lobectomy
- 1 sleeve lobectomy
Of these, 32 fulfilled all inclusion criteria. Of these 32 patients, 17 had at least 
one exclusion criteria:
- 6 had an air leak over 1000 mL/min
- 2 patients had respiratory failure post-op and were kept intubated
- 2 were on immunosuppressive medication
- 2 had evidence of post-operative bleeding
- 2 had fever and tachycardia of unknown etiology post-operatively
- 1 had delirium and urinary tract infection post-operatively
- 1 was on chronic antibiotics for a mandible infection
- 1 had severe post-operative bronchospasm
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As such, 15 patients were invited to be enrolled to this study. Of these 15
patients, 12 consented and received intrapleural dextrose 50%. Three patients 
were not enrolled for the following reasons:
- 1 refused for personal motives
- 1 could not be enrolled because there were no digital drains available
- 1 could not be enrolled because the researchers were not available to
recruit the patient and administer the study agent
The mean (SD) age was 69.2 (5.1) years old. Women constituted 58% (7/12) of 
the patients. A summary of the demographics of the recruited patients is 
displayed in Table 3 and 4. Of note, patient #1 and #11 are in fact the same 
person who underwent 2 distinct surgeries. No patient had preoperative
diagnosis of diabetes, however one (patient #4) was diagnosed with type 2 
diabetes during her hospital stay. All patients had their surgery for oncological 
indications.
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Table 3  Patients demographic. CCI = Charlson Comorbidity Index; VATS = 
video-assisted thoracic surgery; D50 = dextrose 50%; SD = standard deviation.
Variable (n=12) 
Mean (SD) 
Median [Q1  Q3] 
N 
Age (years) 69.2 (5.1) 
Gender M:F 5:7 
Smoking status 
Ex-smoker 7/12 (58%) 
Non-smoker 2/12 (17%) 
Smoker 3/12 (25%) 
CCI 3.5 [2  4.5] 
Diagnosis 
Lung metastases 3/12 (25%) 
Lung nodule 3/12 (25%) 
Lung cancer 4/12 (33%) 
Cancer recurrence 2/12 (17%) 
Surgery 
Lobectomy 8/12 (67%) 
Wedge 4/12 (33%) 
Approach 
Thoracotomy 9/12 (75%) 
VATS 3/12 (25%) 
Air leak pre-D50 (mL/min) 115 [50  332.5] 
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Table 4 Individual patient demographics. CCI = Charlson Comorbidity index; D50 = dextrose 50%; VATS = video-
assisted thoracic surgery. *This patient fit the definition of air leak, but the last value recorded before administration of 
dextrose was 30 mL/min. Those two patients did not receive the full volume as described in manuscript.
Patient # Group (mL)
Volume
received (mL)






1 50 50 72 F 6 ex-smoker lung metastases lobectomy thoracotomy 50
2 50 50 66 M 6
non-
smoker
lung metastases lobectomy thoracotomy 30*
3 50 50 66 M 3 smoker lung nodule wedge VATS 400
4 100 100 63 M 4 smoker lung cancer recurrence lobectomy thoracotomy 110
5 100 100 67 F 4 ex-smoker lung cancer lobectomy thoracotomy 120
6 100 100 71 M 2 smoker lung cancer lobectomy VATS 190
7 150 150 81 F 4 ex-smoker lung cancer lobectomy thoracotomy 490
8 150 150 72 M 2
non-
smoker
lung nodule wedge thoracotomy 310
9 150 150 69 F 3 ex-smoker lung nodule wedge thoracotomy 590
10 200 10 69 F 2 ex-smoker lung cancer recurrence lobectomy thoracotomy 50
11 200 35 72 F 6 ex-smoker lung metastases wedge VATS 100
12 200 200 62 F 2 ex-smoker lung cancer lobectomy thoracotomy 40
51
5.2 PRIMARY OUTCOME
All adverse events, including grade and relationship with the intervention are 
displayed in Table 5. Below are the details of each adverse event.
Patient #1 did not experience any adverse event.
Patient #2 was found to have a knee cellulitis on POD#3. On further
questionnaire, it was found that the patient already had a cellulitis preoperatively, 
but it was not disclosed to the investigators nor the medical team. The patient 
was therefore placed on antibiotics. No other adverse event noted.
Patient #3 had a sputum culture ordered by the nurse on POD#2, without this 
being disclosed to the investigators nor the medical team. The patient was then 
enrolled into the study and glucose was administered. On POD#3, it was found 
that the sputum was positive for 2 bacteria, and intravenous antibiotics were 
started. It was not clear if the patient was just colonized with those germs, or if he 
had a true pneumonia. The Infectious Diseases team was consulted. This 
adverse event was not due to the intervention, as the sputum culture preceded
injection of D50. This patient recovered uneventfully from the pneumonia.
.
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Adverse event Grade Relationship
1 50 50 None n/a n/a
2 50 50 Knee cellulitis 2 not related
3 50 50 Pneumonia 3 not related
Diarrhea - C. difficile 1 not related
4 100 100 None n/a n/a
5 100 100 Atrial fibrillation 2 unlikely to be related
6 100 100 None n/a n/a
7 150 150 None n/a n/a
8 150 150 None n/a n/a
9 150 150 None n/a n/a
10 200 10 Chest wall pain 3 definitely related
11 200 35 Cough 1 definitely related
12 200 200 Atrial fibrillation 2 unlikely to be related
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On POD#6, the patient was found to have diarrhea and was in fact positive for C. 
difficile colitis. This was not felt to be related to the intervention, but rather from 
the use of IV antibiotics.
Finally, an additional chest tube was placed on POD#3, or 22 hours after the 
dextrose was administered. The original chest tube placed in the operating room 
was deemed to be position-dependent by the medical team prior administering 
the dextrose, as reflected by the presence of subcutaneous emphysema a few 
hours post-operatively and the significant variation in the air leak rate ranging 
from 0 to 400 mL/min. The insertion of an additional chest tube was not felt to be 
the original chest tube.
Patient #4 did not experience any adverse event.
Patient #5 had a fasting glucose of 7.7 mmol/L, a HbA1c of 6.2%, and a pre-
intervention glycemia of 12.6 mmol/L. Given these values, Endocrinology was 
-existing pre-
diabetes/mild ty
sliding scale. She received 3 units subcutaneously, and then another 2 units. 
This was not classified as an adverse event. Endocrinology recommended a 
follow-up with the patient General Practitioner on discharge to manage her type 2 
diabetes mellitus.
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The patient developed atrial fibrillation on POD#4 (2 days after dextrose 
administration). She remained asymptomatic and hemodynamically stable and
was fully converted back to sinus rhythm after receiving metoprolol 12.5 mg oral. 
This was classified as a grade 2 adverse event
the intervention.
Patient #6 did not experience any adverse event.
Patient #7 did not experience any adverse event. An additional chest tube had to 
be inserted for a basal space noted on CXR POD#15.
Patient #8 did not experience any adverse event. He tripped on the chest tube 26 
hours after dextrose administration, which led to disconnection of the chest tube 
from the digital drain. When reconnected, there was a new air leak (Figure 5-H,
see below).
Patient #9 did not experience any adverse event.
Patient #10 did experience severe pain after administration of only 10 mL of 
hypertonic glucose. The investigators stopped administration of the intrapleural 
drug, and placed back the tube on suction, aspirating the glucose. Once the 
glucose was outside of the pleural space, the pain subsided. This grade 3 
adverse event is definitely related to the intervention and resolved quickly after 
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the glucose was evacuated. This patient did not have another attempt at D50 
insertion.
Patient #11 did experience mild to moderate cough after administration of an 
initial volume of 20 mL of hypertonic glucose. The investigator paused and
resumed injection of another 15 mL when the administration was stopped 
completely for fear that too much of the hypertonic solution may enter the lung 
parenchyma. The patient was able to taste sugar in her mouth. The chest tube 
was kept above the patient for the usual 2 hours, and then placed back on the 
ground and on suction. This grade 1 adverse event is definitely related to the 
intervention and ceased when we stopped administering the glucose. 
Patient #12 did experience asymptomatic atrial fibrillation on postoperative day 3 
(24 hours after the intervention). The cardiologist mentioned that this was most 




Secondary outcomes are displayed in Table 6 and 7. For the whole cohort, the
median (IQR) length of stay was 6.9 (5.3 8.7) days. Patients were discharged 
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with a one-way valve in 33% (4/12). The median (IQR) time from D50
administration to last chest tube removal was 6.6 (2.6 17.2) days. Mean (SD) 
chest tube output during the first 24 hours after D50 administration was 365 (246)
mL. No patient was discharged on home oxygen, nor readmitted after being 
discharged, nor experienced recurrent air leak. Two patients (17%) required 
additional chest tube after the intervention. 
The evolution of the air leak rate, the glycemia and the pain level over time is 
displayed in Figure 5 for each patient. The vertical red line denotes when D50 
was administered in the pleural space. Administration of intrapleural glucose did 
not increase pain as assessed by empirically inspecting the graphs. Most 
patients (9/12) experienced increase in glycemia (0.1 to 8.2 mmol/L) 1 hour after 
intrapleural administration but this was not clinically significant. Only one patient 
(1/12) received additional treatment to control the glycemia (subcutaneous 
insulin).
There was no reduction in the amount of air leak with a volume of 50 mL of 
dextrose 50% as shown in Figure 5 A-C. However, a flattening of the air leak 
curve was noted at a volume of 100 mL (Figure 5 D-F), and this was even more 
pronounced at a volume of 150 mL (Figure 5 G-I). Flattening of the air leak curve 
was also noted in the group 200 mL (Figure 5 J-L).
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Length of stay (days) 6.9 [5.3 8.7]
Time from D50 to last chest tube removal (days) 6.6 [2.6 17.2]
Output 24h post-D50 (mL) 365 (246)
Glycemia pre-D50 (mmol/L) 7.4 (1.9)
Glycemia 1h post-D50 (mmol/L) 10 (3.4)
Heimlich valve 4/12 (33%)
Additional chest tube required 2/12 (17%)
Additional treatment for hyperglycemia 1/12 (8%)
Empyema 0
Discharged on home O2 0
Readmission 0
Recurrent air leak 0
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Time from D50 to last chest 
tube removal (days)



















1 5.3 9.9 325 7.5 6.1 -1.4 Yes No No No No No
2 7.4 4.9 300 7.2 5.9 -1.3 No No No No No No
3 9.4 18.8 0 6.3 7.3 1 Yes Yes No No No No
4 11 8.1 600 9 10.4 1.4 No No No No No No
5 6 1.7 325 12.6 14.5 1.9 No No Yes No No No
6 4.3 2.0 500 7.3 11.9 4.6 No No No No No No
7 19.4 17.0 775 6.7 14.9 8.2 No Yes No No No No
8 6.3 17.8 400 7.8 9.2 1.4 Yes No No No No No
9 8.1 24.8 200 6.1 11.4 5.3 Yes No No No No No
10 5.3 2.8 100 6.4 * * No No No No No No
11 3.3 0.7 125 6 6.1 0.1 No No No No No No
12 8.5 5.0 385 5.3 12.7 7.4 No No No No No No
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A. Patient #1 B. Patient #2 C. Patient #3
Figure 5 (A-C, 50 mL group) Top graph shows relationship between air leak rate (blue line) and time, and glycemia (orange 
line) and time. Bottom graph shows relationship between pain level and time. Vertical red line represents D50 administration 
in the pleural space.
60
D. Patient #4 E. Patient #5 F. Patient #6
Figure 5, continued (D-F, 100 mL group) Top graph shows relationship between air leak rate (blue line) and time, and 
glycemia (orange line) and time. Bottom graph shows relationship between pain level and time. Vertical red line represents 
D50 administration in the pleural space.
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G. Patient #7 H. Patient #8 I. Patient #9
Figure 5, continued (G-I, 150 mL group) Top graph shows relationship between air leak rate (blue line) and time, and 
glycemia (orange line) and time. Bottom graph shows relationship between pain level and time. Vertical red line represents 
D50 administration in the pleural space.
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J. Patient #10 K. Patient #11 L. Patient #12
Figure 5, continued (J-L, 200 mL group) Top graph shows relationship between air leak rate (blue line) and time, and 
glycemia (orange line) and time. Bottom graph shows relationship between pain level and time. Vertical red line represents 
D50 administration in the pleural space. Patients #10 and #11 each received less than 200 mL of D50 (see text).
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5.3.2 EFFECT OF INTRAPLEURAL DEXTROSE ON THE AMOUNT OF AIR 
LEAKING FROM THE LUNG
The volume of air leaking out of the lung can be approximated using the
trapezoidal rule75 (Appendix J). For each patient, the last 24 hours preceding 
administration of dextrose was calculated, along with the following 24 hours. 
Patients #1-2, #4-7 and #9 had enough data to calculate the amount of air 
leaking for 24 hours prior and after dextrose administration. Patient #3 did not 
have meaningful data before dextrose administration and was therefore excluded 
for the purpose of this analysis. Patient #8 disconnected the chest tube 22.9 
hours after dextrose was administered (Figure 5-H), and therefore only this time 
window was used prior and after dextrose insertion to calculate the amount of air 
prior to dextrose 
administration (Figure 5-J)
dextrose administration (Figure 5-K). The volume of air leaking that was 
calculated for each of these 2 patients was adjusted accordingly to use the same 
time period before and after dextrose (4.1 hours for patient #10, 11.6 hours for 
patient #11). These patients are analyzed as per the intention to treat design.
Individual patient data is presented in Figure 6 (organized according to D50 
volume).
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Figure 6 Volume of air leaking out of the chest in the 24 hours preceding (blue) or following (red) dextrose administration.
For patients #8, #10 and #11, a 22.9 hours, 4.1 hours and 11.6 hours window was used (see text for details).
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Figure 7 shows the effect of intrapleural dextrose on the volume of air escaping 
the lung in the 24 hours (22.9 hours for patient #8, 4.1 hours for patient #10, and 
11.6 hours for patient #11) before/after dextrose administration. There was a 
statistical difference in the mean volume leaked before compared with after 
dextrose administration (221 vs 31 L, p=0.013). Subgroup analysis is shown in 
Figure 8. Using again paired t-test, statistical differences were found in the 
groups D50 100 mL and D50 150 mL (194 vs 31 L, p=0.028 and 503 vs 31 L, 
p=0.036 respectively).
Figure 7 Mean volume of air leaked (L) in the cohort before or after 




Figure 8 Mean volume of air leaked (L) in the cohort before or after 
administration of D50 in each subgroup. ** denotes statistical significance.
Figure 5 showed the relationship between the time after the surgery and the air 
leak rate for each patient, with a vertical bar denoting when D50 was 
administered. There seems to be an immediate decrease in the air leak rate 
following D50 in patients #5 to #12. This decrease was statistically significant 
only for patients #7, #8 and #11 as shown in Figure 9.
****
67
Figure 9, 50 mL group (patients #1-2) Relationship between air leak rate and time after 
surgery, before and after D50.  Raw data from the digital drain is displayed on the left, and data 
analyzed using interrupted time series method is displayed on the right. Shaded area represents 95% 
confidence interval. The impact of D50 is not statistically significant for patient #1 (p=0.651), and is 
statistically significant for patient #2 (p=0.010).
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Figure 9, continued (100 mL group, patients #4-6) Relationship between air leak rate and 
time after surgery, before and after D50.  Raw data from the digital drain is displayed on the left, 
and data analyzed using interrupted time series method is displayed on the right. Shaded area 
represents 95% confidence interval. The impact of D50 is not statistically significant for patient #4 
(p=0.133), patient #5 (p=0.392) and patient #6 (p=0.336).
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Figure 9, continued (150 mL group, patients #7-9) Relationship between air leak rate and 
time after surgery, before and after D50.  Raw data from the digital drain is displayed on the left, 
and data analyzed using interrupted time series method is displayed on the right. Shaded area 
represents 95% confidence interval. The impact of D50 is statistically significant for patient #7 
(p<0.001), patient #8 (p=0.002) but not for patient #9 (p=0.442).
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Figure 9, continued (200 mL group, patients #11-12) Relationship between air leak rate and 
time after surgery, before and after D50.  Raw data from the digital drain is displayed on the left, 
and data analyzed using interrupted time series method is displayed on the right. Shaded area 
represents 95% confidence interval. The impact of D50 is statistically significant for patient #11
(p=0.007) but not for patient #12 (p=0.428). Patient #10 was excluded as only 2 time points were 
available pre-D50.
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5.3.3 EFFECT OF THE INTRAPLEURAL DEXTROSE ON THE CHEST TUBE 
FLUID OUTPUT FROM THE PLEURAL SPACE
For each patient, the 24 hours chest tube fluid drainage was compared before 
and after administration of D50. Patient #11 had her chest tube removed 18 
hours after D50, and therefore only the output of the preceding 18 hours was 
taken into consideration. Figure 10 shows the impact of D50 on the chest tube 
fluid output. There were no statistical differences (282 vs 365 mL, p=0.198). 
Subgroup analyses also did not show any differences (Figure 11). Patient-
specific changes in the chest tube output are displayed in Figure 12.
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Figure 10 Chest tube output in the 24 hours before and after D50 
administration
Figure 11 Chest tube output in the 24 hours before and after D50 
administration, per subgroup
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Figure 12 Chest tube output in the 24 hours before and after D50 administration, per patient
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5.3.4 EFFECT OF THE INTRAPLEURAL DEXTROSE ON THE GLYCEMIA
For each patient, glycemia was measured minutes before dextrose administration 
(baseline), at 1 hour, 3 hours and 6 hours. Findings are displayed in Figure 5
(patient-specific), and in Figure 13 as a mean for the 11 patients for which data 
was available (Patient #10 did not have glycemia recorded after D50 
administration). A repeated-measures ANOVA determined that mean glycemia 
differed significantly across the four time points (F(3, 30) = 5.498, p=0.004). A 
post hoc pairwise comparison using the Bonferroni correction showed an 
increased glycemia between baseline and 1 hour after D50 administration (7.4 vs
10.0 mmol/L), but this was not statistically significant (p=0.156). Therefore, we 
can conclude that the apparent transient increase in blood sugar following 
intrapleural D50 is not statistically significant in our cohort. This could be due to 
the small size of our cohort resulting in a lack of statistical power.
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6 DISCUSSION AND CONCLUSION
6.1 DISCUSSION
Air leaks following lung resection are a cause of prolonged hospital length of 
stay, morbidity and increased costs. Preoperative interventions to prevent them 
are scarce. Some may benefit from being weaned off steroids, or their nutritional 
status optimized76, but patients who would actually benefit from these actions are 
in the minority. Patients with severe bullous emphysema are sometimes offered 
alternative treatment such as stereotactic beam radiation therapy as a way to 
avoid the morbidity associated with surgical resection with mixed results77.
Intraoperative prevention of air leaks involves meticulous fissure-less dissection, 
minimizing residual space, and sometimes the judicious use of sealants78,79.
Benefit in the reduction of postoperative air leaks have been shown on severe 
emphysematous patients with bovine pericardium reinforced staple lines80.
Optimal chest tube management (suction or not) after lung resection is still 
matter of debate81. The European Society of Thoracic Surgeons Early Recovery 
After Surgery (ERAS) consensus recommends against the routine use of 
suction82, but comments that the available evidence is conflicting. 
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When there is persistent air leak postoperatively, several strategies including 
observation-only, placement of a one-way valve, bedside chemical pleurodesis, 
blood patch, reoperation with possible muscle flap or pneumoperitoneum are 
options available to the clinician83. All these approaches have their pros and 
cons. As mentioned in the Literature Review, there are several agents used for 
chemical pleurodesis. Hypertonic glucose has emerged as an agent which may 
have the bad publicity talc had in recent years59,84. Patients undergoing lung 
cancer resection often have surgery as part of a multimodality plan of care and it 
is critical that they avoid post-operative infectious complications occasionally 
associated with prolonged air leaks.
The mechanism in which hypertonic glucose may induce pleurodesis is unknown. 
Pleurodesis often involves a systemic reaction leading to increased erythrocyte 
sedimentation rate, C-reactive protein, leukocyte count, and a febrile state. Ukale 
et al. showed that the degree of patient systemic response to either talc or 
quinacrine correlated with pleurodesis success85. Teixera37 39,86,87 et al. worked 
extensively on the physiology of pleurodesis in their experiments with New
Zealand rabbits using talc or silver nitrate. Following introduction of a sclerosing 
agent in the pleural space, damage to mesothelial cells occur. This leads to 
neutrophilic exudate and secretion of several cytokines (IL-8, VEGF and TGF- 1). 
This in turns alters the balance between metalloproteinases and plasminogen 
activators and affects 
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Pleural fibrosis becomes evident one week after the insult. Pleural adhesions are 
still maturing at 4 weeks while the active microscopic pleural inflammation is 
already declining. It is unclear how hypertonic glucose may induce pleurodesis. 
The osmolarity of the 50% glucose solution used in this trial is 2526 mOsm/L,
and a pH of 4.2. This is in contrast to plasma osmolarity in the range of 275
299 mOsm/L. Direct mesothelial cell damage may occur, as mentioned above. 
This 50% glucose solution, while liquid, also has the property to 
syrup. Another mechanism of how this hypertonic solution seals air leaks could 
be by mechan plug
While the first documented use was reported in 1906, hypertonic dextrose is still 
not very commonly used compared to other chemical pleurodesis agents it is 
unclear why. We postulate practitioners view other agents as more aggressive 
and irritant for the pleura and thus leading to better pleurodesis. Our systematic 
review showed that the dextrose concentration, volume, duration, frequency, 
timing, and use with additional adjuncts varied greatly. In this era where ERAS is 
promoted, treatment of air leaks by an agent widely available, easy to store, safe, 
and effective is encouraged.
6.1.1 ABOUT THE OUTCOMES
This study verse events. The Data 
and Safety Monitoring Board rigorously assessed all reported event, evaluated 
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the relationship with the intervention (administration of glucose) and then issued 
recommendation as to whether continuation of the study was possible. A 
member of the DSMB is also a thoracic surgeon who attended the weekly 
Thoracic Surgery review of adverse events, further consolidating the oversight of 
this Board on this trial. A DSMB halting rule chart was available to guide them in 
their recommendation. 
In our cohort, no major or severe adverse event was noted. Two patients had an 
episode of atrial fibrillation on POD#3-4, or 1-2 days after receiving the glucose. 
Supraventricular arrhythmias are common after lung resection. In these particular 
instances
, and a cardiologist stated that this tachyarrhythmia was probably 
preexisting the surgery. Two non-dose related adverse events happened in the 
200 mL group. Patient #10 had immediate, severe chest wall pain after injecting 
only 10 mL of the solution. The pain was severe enough that the patient wished 
to stop the procedure. The solution was aspirated from the chest and the pain 
subsided immediately. It is not clear why this patient experienced this degree of 
discomfort. One hypothesis is that she must have had some pleuritis where the 
tube abutted. Patient #11 developed clinically significant cough during 
administration of the hypertonic solution and could taste it in her mouth. This was 
the case despite the air leak rate being only 100 mL/min which was in the 
acceptable range. Leaks over 1,000 mL/min were deemed too large, and thus a 
surrogate of a large defect in the lung parenchyma with higher potential for 
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aspiration of the pleural fluid into the lung and the airway, increasing the risk of 
pneumonitis and/or respiratory distress. It is worth mentioning that those 2 
adverse events were triggered at a volume inferior to the minimal increment 
tested (50 mL). Both patients did well, and it highlights the clinical judgement 
required when administering intrapleural solutions. One strategy that could have
possibly helped mitigating both situations would have been to administer local 
anesthesia (lidocaine) prior to D50 insertion in the chest. Lidocaine was selected 
to be administered following the D50 in order to flush the tube of any residual 
dextrose solution, out of the theoretical apprehension that the chest tube could 
possibly clog if this hypertonic solution sits for 2 hours before the tube placed 
back on suction. Administering the lidocaine first could block the nociceptive 
stimulus triggered by dextrose on the parietal pleura. However, if a sizable 
pleuroalveolar communication exists, lidocaine could also blunt the coughing 
reflex leading to more dextrose ultimately going into the lung and airway. We 
propose an approach that would administer 10 mL of lidocaine first, and then
flush the tube with another 10 mL after introducing the dextrose.
Intrapleural glucose led to a significant reduction in the volume of air leaked. Post 
hoc exploratory analyses were performed. For the entire cohort, the reduction in 
the mean volume leaked was 86% (from 221 L to 31 L). There appeared to be a 
dose-response effect (Figure 6). The effect of the glucose on air leak reduction 
was assessed both empirically inspecting the air leak rate over time graphs 
(Figure 5) and statistically (Figure 9). The decision to remove a chest tube after 
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lung surgery depends mostly on a reduction of the air leak, but it is unclear how 
much air can still be leaking before the chest tube can be removed without 
needing to reinsert one. Gilbert et al.29 have suggested that a chest tube can be 
removed safely with an active air leak of up to 30 mL/min (or 43.2 L / 24 hours). 
Our trial suggests that D50 does reduce the volume of air leaks after lung 
surgery and may have a role in expediating the removal of chest tubes. A volume 
of 150 mL appeared to be optimal.
Our trial did not address the effect of repeated intrapleural dextrose 
administration, but it is theorized that it could lead to further reduction in the 
volume of air leaking from the lung parenchyma. In the systematic review, 2
papers6,52 described repeated administration after a first fail attempt in 
retrospective cohorts. Sumitomo described that the 2 patients who had repeated 
D50 sealed their leak. Additionally, Fujino described reported that out of 18 
patients who did not seal their leak immediately after a first attempt, 8 had a 
successful second injection.
The outcome used was the volume of air leaked and not the air leak rate as while 
excellent interobserver reliability using the Medela ThopazTM was reported28, our 
data shows that there can be significant variation of the air leak rate over time, 
both before and after the pleurodesis. A patient with several spikes of air leak 
overnight who would then have a much smaller leak when assessed by the 
medical team a few hours later may not have his tube removed by fear of the 
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leak reactivating. This scenario is not that uncommon, and perhaps using the 
total volume of air leaked in a certain time frame may be a better metric in certain 
circumstances than looking only at the flow. The question then would be when, 
after dextrose injection, would the air leak rate be documented and compared to 
the pre-pleurodesis value to ensure success of the air leak resolution. Chest tube 
are typically removed when the fluid output falls under a certain threshold. Since 
the chest tube purpose is to evacuate both fluids in the pleural space and the air 
potentially leaking from the lung, it made sense to treat both states as volumes 
for statistical considerations.
Contrary to some reports6,53, there were no dramatic increase in the chest tube 
fluid output following dextrose administration. Fujino reported on a patient who 
drained 780 mL of fluid in the 2 hours following D50 after the tube was placed 
back on suction. The mean volume drained after successful pleurodesis was 605 
mL, and this was significantly higher than in patients who did not have successful 
pleurodesis (297 mL). Takanashi reported on a 97-year-old man with 
spontaneous pneumothorax who received 400 mL of D50, and subsequently 
drained 1,960 mL of fluid over 4 hours. This led to severe dehydration, acute 
kidney injury and resultant ischemic colitis from hypoperfusion. The patient was 
treated conservatively and recovered. We did not see such increase in the chest 
tube output following D50 administration in the present study, but this may be 
due to the relative lower volume used in this trial compared to others.
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Most patients had a slight increase in their glycemia, although it was not 
statistically significant, and it reverted back closer to baseline within 3 hours. This 
is similar to Tsukioka et al. findings8. In our trial, nobody had preexisting 
diabetes. One patient was diagnosed as having diabetes by Endocrinology the 
day she was enrolled in the study. She required a minor amount of supplemental 
subcutaneous insulin (total of 5 units in 2 divided doses) and there were no 
clinically significant adverse events.
6.1.2 LIMITATIONS
Our study has some limitations. This is a small cohort of patient and hence, any 
statistical analyses are subject to a lack of power. The COVID-19 global 
pandemic was declared just one day prior to this study started to screen patients. 
Operating room shutdown led to decrease surgical volumes. To compensate the 
lack of OR time, we had started doing cases by thoracotomy instead of video-
assisted as these surgeries are typically performed faster open. We anecdotally 
noticed that this led to a decline in the incidence of air leaks, presumably due to 
gentle retraction of the lung parenchyma during thoracotomy compared to tight 
grasp of a thoracoscopic grasper. The lack of postoperative air leaks hindered 
patient accrual.
There are some missing data that limit our ability to perform some analyses. 
However, we believe our results are robust because the safety profile of D50 at 
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the volume used in the current prospective trial corresponds to findings from 
retrospective studies. In addition, some missing data are in fact on air leak flow 
due to early chest tube removal secondary to rapid pleurodesis.
This study is performed in one center only, and better external validity could be 
achieved if a multicenter trial is performed. We are hoping to invite other centres 
in the next phase of this research.
6.1.3 STRENGTHS
This study is one of only two to prospectively evaluate the safety of the bedside 
administration of hypertonic glucose to treat post-operative air leak. The other 
prospective study on the topic was performed by Albargawi et al. also from our 
institution and has only presented in abstract9. The current study has several 
differences. First, this is a Phase I trial assessing safety and collecting data to 
assist in designing a phase II trial down the road. Information on air leak 
resolution, chest tube removal or length of stay are all data that will be useful for 
sample size calculation and research planning. Rigorous oversight by regulatory 
agencies (Health Canada) and a DSMB was required. Secondly, we used a rule-
based escalation, traditional 3+3 design to move to the next dose threshold. This 
approach is considered the standard and is commonly used when new drugs 
need to be approved, notably in oncology. This makes the methodology very 
robust.
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Our study prospectively collected data. To minimize selection bias, all 
consecutive patients were screened and considered for the trial. There were no 
patients lost to follow-up. There was consistent and thorough reporting and 
oversight by a diverse group of experts on the DSMB throughout the study.
We used a commercially available product from Hospira/Pfizer as our study 
agent rather than requiring our hospital pharmacy to prepare the D50. This was 
considered superior because: it was more convenient in terms of storage, more 
convenient for the researchers to have immediate access to the drug including 
during weekends, it was more cost effective by not requiring a pharmacy 
technician to prepare an immediate-use injectable for research purposes while 
clinical work may have been requested at the same and we secured doses for 
the whole Phase I trial.
The process in which the drug was administered was very standardized, starting 
by confirming the presence of a leak using a digital drain system, administering 
the drug to all patients on POD#2, having only one researcher who obtained 
consent and administered the study agent to be the most consistent possible. 
This leads to reliable data, with good internal validity.
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6.2 FUTURE DIRECTIONS
Exploratory analyses in this cohort have shown that there is some efficacy in the 
use of intrapleural administration of dextrose 50% to treat air leaks. We arbitrarily 
elected to dispense this drug once, but perhaps there could be a role for 
repetitive administration of intrapleural glucose. Additionally, intrapleural glucose 
was administered intraoperatively in a few papers, including in Tsuboshima47 et 
al. trial where 50 mL of D50 was sprayed over the staple line and an absorbable 
mesh to prevent recurrent spontaneous pneumothoraces. This may have the 
drawback to expose some patients to D50 while they may not have needed. 
Performance of bedside pleurodesis as early as POD#1 instead of POD#2 could 
be done. This would potentially lead to further reduction of the hospital length of 
stay. Administration of D50 on POD#2 was chosen for practical reasons: due to 
the scarcity of Medela ThopazTM at our institution when the trial was designed, 
we were apprehending that too many of these digital drains may be used, 
preventing patients with other clinical indications (large leak and need to 
ambulate, prolonged air leak with lung collapse when off suction) from being able 
to utilize them. We now have access to more of these drains. In addition, this trial 
primarily assessing safety performing the intervention later in the postoperative 
course prevented recruiting patients who may have had unrelated adverse 
events that would have happened between POD#1 and POD#2. Out of the 32
patients who met inclusion criteria, 4 were excluded for adverse event that could 
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have been attributed to D50 but would in fact not be linked to the intervention (2
had fever/tachycardia of unknown etiology on POD#1 or early POD#2, 1 had 
severe post-operative bronchospasm late POD#1 early POD#2, and 1 had 
delirium and urinary tract infection on POD#1). Due to the design of our Phase I, 
those events may have jeopardized the ability to pursue to study further, even if 
the plausibility of a relationship between D50 and those events is small. Adverse 
events would be recorded during a Phase II trial, but this would not be the 
primary outcome. In addition, initial concerns were raised on whether post-
operative bleeding would clog tubing of the Medela Thopaz easily (the diameter 
is smaller than the standard analog drainage system). This worry did not 
materialize. Lastly, performing the intervention on POD#2 meant being able to 
introduce the study to patients on POD#1, and have time to obtain consent by 
POD#2. Since we now have a track record using D50, patients may be able to 
give consent sooner.
6.3 CONCLUSION
In conclusion, intrapleural administration of glucose 50% at a volume ranging 
from 50 mL to 200 mL on post-operative day 2 after lung resection surgery to 
treat air leaks appear safe and well tolerated. Optimal dose is 150 mL.
Precautions during the intrapleural administration have to be taken to detect and 
prevent increased chest discomfort or severe cough. Further work is needed to 




7  PROPOSAL FOR A PHASE II TRIAL
The next phase is to evaluate the efficacy of intrapleural glucose in treating post-
lung resection air leaks in a randomized pilot Phase II trial. To our knowledge, 
this would be the first prospective randomized trial assessing efficacy and 
effectiveness of D50 in reducing prolonged air leaks in patients undergoing lung 
resection.
7.1 HYPOTHESIS AND OBJECTIVES
Question: the administration of 150 mL of 50
air leak
Hypothesis: Intrapleural D50 at a volume of 150 mL repeatable once (2 
injections maximum) is effective at treating post-lung resection air leaks.
Objective: To evaluate if the postoperative intrapleural instillation of D50 in 
patients undergoing surgical lung resection will decrease the duration of chest 
tube drainage (air leak resolution) compared to placebo. 
7.2 PROJECT PLAN
To further define efficacy of intrapleural dextrose in sealing post-operative air 
leaks, we would like to perform a multicentre, double-blind, randomized 
controlled trial between administration of intrapleural dextrose vs. placebo. Trial 
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flowchart is detailed in Figure 14. Twenty patients per group are required. This 
phase II trial would have the following PICO: 
Population: 
Adult patients undergoing lung resection surgery for cancer
The air leak would need to be present and confirmed on POD#1 (at least 100
mL/min documented)
Intervention: 
Intrapleural administration of 150 mL of D50 on POD#1
D50 can be repeated on POD#2 if there is still evidence of air leak
Comparison:
Intrapleural administration of 150 mL of placebo (normal saline) on POD#1, to
be repeated on POD#2 if there is still evidence of air leak
Outcome: 
The primary outcome will be the duration of chest tube drainage (DCTD),
defined as the time between completion of surgery and last chest tube
removal
Two secondary outcomes of importance are the time to last chest tube
removal (TCTR), defined as the time between intrapleural injection and last
chest tube removal, and the time to air leak resolution (TALR), defined as the
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time between intrapleural injection and the air leak volume in 12 hours falling 
under a predefined threshold depending on if intrapleural suction is applied or 
not 
Additional secondary outcomes would include quality of life using the
Functional Assessment of Cancer Therapy-Lung (FACT-L)88, the EQ-5D89
and the SF-3690 instruments, pain levels, narcotics consumption, adverse
events (Ottawa Thoracic Morbidity & Mortality System)91 and their relationship
with the study agent, and all the other endpoints collected during our Phase I
trial
Figure 14 PLUG-2 trial flowchart
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7.3 SAMPLE SIZE CALCULATION AND DATA ANALYSIS
A peak air leak over 100 mL/min has been shown to be a predictor of prolonged 
air leaks (OR 4.97) by Takamochi et al.92, and thus increased morbidity. This 
population is the one we are planning to target in our Phase II study using 150 
mL of intrapleural dextrose 50%, volume that should be effective at stopping the 
air leak and reducing the duration of chest tube drainage (DCTD).
Chest tubes can be safely removed on patients if, over the last 12 hours, air leak
rate has dropped to < 40 mL/min if the drain is on suction, or < 20 mL/min if the 
drain is not on suction as per Gilbert et al.29 work.
Four individuals in our Phase I study received a volume of D50 > 150 mL. All 
those patients had a peak air leak > 100 mL/min before D50. Effect on the air 
leak was remarkable. They would have been included in the Phase II study. Their 
air leak rates have decreased dramatically after injection of D50. Using Gilbert 
criteria for safe chest tube removal and accounting for chest tube removal in the 
morning as standard safe practice, those 4 patients would have kept their chest 
tubes a mean duration of 3.04 days (SD 0.48) since completion of surgery. This 
is deemed the expected mean DCTD in the experimental arm (D50).
In Takamochi et al., 27 patients had a peak air leak > 100 mL/min. Mean + SD 
duration of chest tube placement in this group was 5.9 + 2.9 days. Of note, 48% 
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of these patients did have prolonged air leak. This group is considered the 
control arm for sample size calculation purposes. The aforementioned mean (5.9 
days) is likely conservative as some patients may have received sclerosing 
agents if they were leaking for more than 5 days. The mean DCTD of a true 
control group (placebo only) is probably higher (resulting to an even larger 
difference between Takamochi paper and our D50 Phase I trial).
We use the following formulas to calculate the sample size for two independent 
samples, continuous outcomes (Clinical Research for Surgeons93 and Pr Lisa 
Sullivan course94):
d effect size. An of 0.05 and a of 0.2 for a power of 80% 
are desired. reflects the standard deviation of the outcome variable. This is not 
known, but can be estimated by generating Sp, the pooled estimate of the 
common standard deviation derived from the 2 aforementioned studies (D50 
Phase I trial and Takamochi paper). There, n1 is the sample size of the D50 study 
(4), s1 is the SD of the D50 study (0.48), n2 is the sample size of Takamochi 
group (27), s2 is the SD of Takamochi group (2.9). The Sp generated is 2.75. 
Using this Sp in lieu of and with = 1 2 where 1 is 3.04 and 2 is 5.90, we
obtain a sample size per group of 14.5 (rounded up to 15). 
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Alternative calculation is performed to evaluate the sample size needed to reach 
a power of 80% to detect a difference of 2.86 days (5.90 3.04) in the duration of 
chest tube placement with an of 0.05. The Cohen d 1
= 3.04, 2 = 5.90, = Sp = 2.75). ES is therefore 1.04. This effect size is 
considered large95, which corresponds to our expectation of the impact of D50 on 
air leak rate. Using this parameter, we can plot the power of an eventual Phase II 
96 on RStudio74:
Figure 15 Power calculation PLUG-2 trial
Based on this calculation, 16 patients per group would lead to an adequately 
powered study, which is similar to the previous calculation.
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It is not known if the duration of chest tube drainage will be normally distributed in 
each group, and thus compared using two sample T test. If it is not, a 
nonparametric test will have to be used (Mann-Whitney U test). Increase of 15% 
of the sample size is recommended to maintain sufficient power if the sample 
size was calculated with the assumption of a normally distributed primary 
outcome when it was not97. Generally, endpoints in health care studies are more 
likely to be positively skewed (and therefore not normal). In addition, to account 
for a 10% loss of follow-up, further rise in the sample size is warranted. In 
summary, a sample size of 20 patients per group is considered as satisfactory.
Intention to treat and per protocol analyses will be applied. Mann-Whitney U test 
will be used to compare median DCTD between groups as mentioned above.
Chi-
patients with prolonged air leak (> 5 days) between groups. Secondary outcomes 
will be evaluated using parametric and nonparametric statistical tests 
accordingly. Univariate and multivariate logistical and linear analyses to assess 
association between outcomes and baseline characteristics (sex, Charlson 
Comorbidity Index, type of resection, surgical approach, smoking status, air leak 
rate) will be conducted. An interim analysis assessing safety, efficacy, and 
possibly to adjust the volume of D50 to 200 mL will be performed when 50% of 
the sample size population is reached. 
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7.4 EXPECTED RESULTS AND SIGNIFICANCE
We propose an achievable sample size of 40 patients (20 per group) that should 
demonstrate a decrease in the DCTD with D50. We selected this endpoint as it is 
an objective patient-oriented outcome. We assume chest tubes are painful and 
patients do not like them. There has not been a validated instrument for QoL 
after oncological lung resection surgery this is the closest endpoint there is. 
Based on our Phase I study, accrual could be completed in about 1 year if one 
additional centre participates.
We anticipate that D50 will replace talc as our pleurodesis agent of choice and 
become the new standard for sealing air leaks following lung resection surgery. 
Should we be successful in mitigating post-operative air leaks in patients 
undergoing lung resections, we will reduce their hospital length of stay. This 
intervention should improve patient outcomes by shortening the duration that a 
chest tube is required in the pleural space, minimizing post chest tube removal 
pneumothoraces, lessen chest tube-related pain, decrease the risk of post-
operative infections, and health care costs. Should this simple, inexpensive, and 
novel therapy work to heal pulmonary air leaks, it will be a significant 




Accrual of patients may be slowed down by the ongoing COVID-19 pandemic 
and ORs shutdown. Additionally, accrual could be slow if thoracic surgeons are 
reluctant to consent patients for this study.
It took 9 months to accrue 12 patients in the present study in a single center.
Involvement of at least another center will allow us to complete the study in a 
reasonable time frame. 
Given the fact that we already obtained Health Canada approval to run this 
Phase I study, it is likely that we will be able to proceed with a Phase II study 
from a Research Ethics Board perspective.
Funding could be granted via a London Regional Cancer Program (LRCP)
Catalyst grant as the patient population studied is mostly recovering from 
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PROTOCOL SUMMARY
Title: PLeurodesis Using hypertonic Glucose administration to 
treat post-operative air leaks following lung resection 
surgery (PLUG): Phase I trial.
Précis: Patients with air leaks on postoperative day 2 following 
lung surgery will be invited to participate in the study. The 
precise definition of air leak is included in inclusion criteria. 
Dextrose 50% (D50) will be injected sterilely into the chest 
tube following the administration of 20 mL of 1% lidocaine. 
Twenty-four hours after the intervention, if there is an air 
leak cessation (defined elsewhere), chest tube removal 
will be considered by the surgical team. If an air leak is still 
present, no further intervention will be planned. The exact 
time of cessation of air leak, time of chest tube removal, 
date of discharge, and any adverse events will be 
prospectively recorded. The volume of D50 administered 
is incremental and will follow a rule-based escalation, 3+3 
design: 3 patients will have a set dose, and if there are no 
dose-limiting toxicities or less than 2 moderate toxicity, the 
next group of 3 patients will go up one increment following 
review from the study safety committee to insure the 
acceptability of the treatment according to its side effects. 
The safety committee will meet every 4 weeks to review 
adverse events. The empiric increments will be 50 mL, 
100 mL, 150 mL, and 200 mL. Therefore, a maximum of 
12 patients will have to be enrolled. 
Objectives: The primary outcome is safety as defined by the lack of a 
grade 3, 4, or 5 adverse events at any given D50 volume 
according to the Common Terminology Criteria for 
Adverse Events of the National Cancer Institute version 
4.0. Secondary outcomes include the persistence of the 
air leak at 24h, 48h and 72h following the intervention, the 
pain score and point-of-care glucose measurement at 1h, 
3h, 6h and 24h after the intervention, the pain level using 
a visual analog scale at 1h, 3h, 6h, and 24h after 
intervention, the output from the chest tube during the first 
24h after the intervention, the length of hospital stay, the 
duration of chest tube drainage, the need to discharge the 
patient with a one-way valve, the need for an additional 
chest tube insertion, the increase in supplemental oxygen 
requirements, the air leak rate, and the post-operative 
morbidity. In addition, patient analgesia consumption will 
be monitored, including the type of analgesia and the 
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route of administration until the earliest between discharge 
day versus post-operative day 5. Also, the need for an 
intervention to address hyperglycemia will be monitored, 
including what type of intervention (insulin administration?) 
and the length of intervention. All of the above outcomes 
will be measured until post-operative day 5, except for 
potential infectious complications which would be 
measured until post-operative day 14. The recurrence of 
an air leak at 60 days will also be monitored.
Population: Total of 12 adult patients (18 years or older) following lung 
resection surgery with an active air leak on post-operative 
day 2 in London, Ontario.
Phase: 1
Sites: 1 Victoria Hospital, London Health Sciences Centre, 
London, ON
Description of study agent: Dextrose monohydrate injection USP 50% 
concentration (50 mg/mL). Volume of 50 mL, 100 mL, 150 
mL, or 200 mL
Study duration: Approximately 2 months
Participant duration: Approximately 3 months
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2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE
2.1 BACKGROUND INFORMATION
Pulmonary air leaks from unhealed lung tissue is one of the most common 
complications after lung surgery. This adverse event leads to a delay in chest 
tube removal, prolonged pain, increased infections, prolonged hospital stay, and 
increased costs to the health care system1. Different agents have been used to 
heal air leaks by pleurodesis but the success and safety profile of these agents 
has been variable. Instillation of a talc slurry into the pleural space is our current 
preferred method in stopping air leaks after lung resection. This technique can 
cause an acute lung injury and the long-term effects of talcosis remain a concern 
to some practitioners and some patients2,58,98. There has been recent interest in 
the use of hypertonic glucose (D50) to create pleurodesis from encouraging 
reports coming from Asia6 8,49. We have performed a pilot study using 180 mL of 
50% hypertonic glucose instilled through the chest tube for the management of 
post lobectomy air leak and the results were encouraging9.
Summary of all data
The search was completed on April 16, 2019 using the terms (dextrose OR 
glucose) AND pleurodesis on PubMed and Google Scholar. Abstracts, 
articles,and their bibliographies were reviewed to find more studies. 
Articles where the intervention was intrapleural administration of any volume of 
hypertonic glucose were included. If the dextrose was administered 
concomitantly with another agent (such as talc), the study was rejected.
A total of 18 studies were found, covering 275 patients (Table 1). The 
concentration of Dextrose ranged from 20% to 50%. The volume of intrapleural 
dextrose during initial administration ranged from 60 mL to 500 mL. The maximal 
total volume administered was 1500 mL (3 times 500 mL over 3 days).
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Table 1. List of all studies. VATS: video-assisted thoracic surgery, POD: post-operative day. a,b,c cf description of the events in the text
Author Year Study design Location n Population Intervention Adverse events 
Chen34 2010 case series China 5 post-esophagectomy 50% glucose + 0.1% lidocaine (volume?) through the 
tube 
self resolving dyspnea 
Chung49 2008 cohort South Korea 49 primary spontaneous pneumothorax thoracoscopic procedure (bleb 
resection/bullectomy/electrocoagulation) + 
instillation of dextrose 20% 200 cc 
rate of fever 22% (dextrose group) vs 10% (no 
dextrose group) 
Tsukioka7 2013 cohort Japan 20 secondary spontaneous pneumothorax VATS bullectomy + mechanical abrasion + dextrose 
50% (500 cc) 
1 deatha 24 days after the surgery from a 
pneumonia,1 prolonged air leak (15 days), 2 
prolonged thoracic drainage, 1 , 
transient elevation of blood sugar  
Hamada10 2017 case series Japan 2 spontaneous pneumothorax 1- 200 mL of dextrose 50% 
2- 400 mL of dextrose 50% 
2 deathsb 
Peng50 2002 case series China 45 recurrent pneumothorax 60-80 mL of Dextrose 50% through the tube 7/45 had mild pain
Chee44 1992 case report Singapore 1 spontaneous pneumothorax 50 mL dextrose 50% pulmonary edemac 
Fujino6 2016 cohort Japan 46 35 post-lung resection patients with air leak 
and 11 patients with pneumothorax and 
prolonged air leak with a tube in place 
200 mL of 50% glucose, between 1 and 3 doses, 7 
patients had OK-432 after their 3rd dose for failure of 
the glucose to work 
mild transient hyperglycemia in 20/46 patients 
Takanashi53 2015 case report Japan 1 spontaneous pneumothorax 50% glucose, 400 mL ischemic colitis secondary to severe dehydratation 
(1960 mL/4 hours), prerenal acute renal failure 
Togo54 2016 case series Japan 29 14 pneumothorax, 11 post-lung resection air 
leak, 4 malignant pleural effusion 
200 mL of 50% glucose (2 patients had 100 mL for 
« poor performance status ») 
Mild transient hyperglycemia, chest pain and fever 
Tsukioka8 2013 case series Japan 13 spontaneous pneumothorax 200 - 500 mL 50% glucose through the tube, they 
often required more than one treatment 
2 "bacterial pleuritis" (both of them required more 
than 1 treatment, and they had their tube 25 and 35 
days, treated with antibiotics only), 1 aspiration 
pneumonia 
Albargawi9 2016 cohort Canada 10 post-lobectomy air leak 200 mL dextrose 50% with lidocaine, one or twice mild increase in chest tube output, mild increase in 
blood sugar 
Frick45 1990 case series Germany 32 spontaneous pneumothorax thoracoscopic pleurodesis with electrocoagulation of 
bullae, visceral/parietal pleurae cauterized, chemical 
pleurodesis with dextrose 50%
Horner syndrome (secondary to pleural cauterization) 
Sumitomo52 2017 case series Japan 13 post-lung resection air leak 200 mL glucose 50%, repeated as needed (2 patients 
had pleurodesis twice) 
none
Kitagata55 2018 case report Japan 1 leak post right lower lobectomy glucose 50% none 
Yaginuma56 2016 case report Japan 1 spontaneous pneumothorax on mechanical 
ventilation 
pleurodesis with glucose 50% and minocycline none 
Kajikawa57 2017 case series Japan 5 spontaneous pneumothorax pleurodesis with 200 mL glucose 50% transient hyperglycemia
Wei99 2016 case report China 1 hydrothorax secondary to peritoneal dialysis 
catheter
diaphragm repaired, pleural effusion evacuated, and 
pleurodesis performed with dextrose 50%
? 
Hennell42 1939 case report US 1 Chronic pneumothorax glucose 50% 50 mL, then 60% 67 mL none 
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2.2 RATIONALE
Air leaks from unhealed lung tissue are one of the most common complications after 
lung surgery including wedge resection, segmentectomy and lobectomy. Air leaks can 
lead to a delay in chest tube removal, prolonged pain, increased infections, prolonged 
hospital stay, and increased costs to the health care system1. Different agents have 
been used to heal air leaks by creating a pleurodesis (adhesions to obliterate the pleural 
space between the visceral and parietal pleura). The success with these agents has 
been variable and come with the cost of complications that have restricted their use the 
post-operative period2. There has been recent interest in the use of D50 to create 
pleurodesis with encouraging reports coming mostly from Asia6 8. We have performed a 
pilot study using D50 instilled through the chest tube for the management of post 
lobectomy air leak with encouraging results9. This preliminary study used strict inclusion 
criteria of only lobectomy patients and excluded many other patients such as patients 
with diabetes or any postoperative hyperglycemia that may benefit from this 
intervention. Also, the optimal dose of D50 was chosen empirically and never clearly 
defined by previous work. It has been reported that high doses of D50 was associated 
to acute lung injury10. It is therefore critical that the optimal safe dose is clarified. 
Objective: To define the most appropriate safe dose of D50 to heal air leaks in patients 
that have undergone lung resection surgery (Phase I study).
Hypothesis: In patients with a postoperative air leak following lung resection, the 
bedside administration of D50 into the pleural space on postoperative day 2 is safe 
(Phase I trial).
We predict that D50 will be found safe because no severe adverse events occurred with 
optimum dose found in the Phase I study. This will provide the motivation and data to 
proceed with a formal Phase II study to assess the effectiveness of the chosen dosage 
in reducing the length of stay and length of chest tube drainage, and then a Phase III 
randomized clinical trial. 
We anticipate that D50 will replace talc as our pleurodesis agent of choice and become 
the new standard not only for sealing air leaks following lung resection surgery but also 
achieving pleurodesis for chronic pleural effusions. Should we be successful in reducing 
postoperative air leaks in patients undergoing lung resections, we will reduce their 
hospital length of stay. This intervention should improve patient outcomes by shortening 
the duration that a chest tube is required, reducing post chest tube removal 
pneumothoraces, decrease chest tube related pain, decrease the risk of postoperative 
infections, hospital length of stay, and health care costs. Should this simple, 
inexpensive, and novel therapy work to heal pulmonary air leaks, it will be a significant 
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2.3 POTENTIAL RISKS AND BENEFITS
2.3.1 KNOWN POTENTIAL RISKS
A literature review is summarized in the Table 1. In five papers6,9,52,54,55, the population 
studied were post-lung resection patients with air leak (70 patients). In these 70 
subjects, reported adverse events were as follow:
mild transient hyperglycemia (n=26/70)
mild transient chest pain
mild transient fever
mild increase in chest tube output
In these 70 patients, reported adverse events were mild. This population is similar to the 
population we plan to study. The concentration of dextrose was 50%. Except for one 
study55 in which the data was not available, they all had administration of 200 mL, 
repeated up to 2 other times for a total of 600 mL over 3 days. There was no infectious 
complication.
In all 275 patients, infectious complications related to the intervention were rare. One 
study7 where 20 patients underwent a bullectomy, mechanical abrasion and 
administration of 500 mL of Dextrose 50% in the operating room had one case of 
thoracic drainage and the volume of air leakage may contribute to the development of a 
nother study8 where 13 patients had spontaneous pneumothorax 
treated with a chest tube and then administration of between 200 to 500 mL of dextrose 
50%, repeated up to a total of 3 times (500 mL administered 3 times over 3 days) 
for a prolonged period of time (25 and 35 days), and they both had repeated 
administration of 500 mL of dextrose 50% (one had a total of 2 doses and the other 3 
doses). All these 3 patients were treated conservatively with antibiotics.
Ischemic colitis induced by dehydration was reported after the administration of 400 mL 
of Dextrose 50% on a 97 years old gentleman to induce pleurodesis after a 
spontaneous pneumothorax53. This was treated conservatively with rehydration and 
surgery was not required.
Chee44 reported a case of dextrose pneumonitis. The 51 years old male with chronic 
obstructive airways disease complicated by cor pulmonale and hypercapnic respiratory 
failure had a spontaneous pneumothorax. He had a prolonged air leak for 41 days. 
Intrapleural instillation of 50 mL of Dextrose 50% was performed and the patient 
experience cardiorespiratory collapse requiring cardiopulmonary resuscitation. It was 
noted that copious amount of secretions was coming from the endotracheal tube,
positive for glucose by a dipstick. The patient recovered well after that event and the 
leak stopped. It was postulated that osmotic pulmonary edema may have been caused 
by the high tonicity of the dextrose 50%.
PLUG-1 Version 2.05
Protocol MQRM711                                                                                    11 July 2019
Clinical Trial Protocol v2.05 20190711 6
Of the 275 patients who underwent intrapleural hypertonic dextrose administration for 
pleurodesis, a total of 3 deaths were reported.
4- In Tsukioka7 paper, a 79 years old male with severe emphysema, unresectable 
lung cancer who recently had chemotherapy, underwent a bullectomy, 
mechanical abrasion of the pleura, and administration of 500 mL of dextrose 50% 
in the pleural cavity. Twenty-four days after his surgery, he passed away from a 
pneumonia. It is unclear whether his death is related to the administration of a 
sclerosing agent.
5- In Hamada10 paper, a 72 years old male with a stage IV lung cancer and severe 
emphysema, presented with spontaneous pneumothorax. He was first treated 
with 5 rounds of OK-432 (sclerosing agent available in Japan to induce 
pleurodesis), but it did not work and the leak was still present. Then, 4 rounds of 
autologous blood and 200 mg of minocycline were injected into the pleural cavity 
via the chest tube, again without success. Finally, 200 mL of dextrose 50% was 
injected into the pleural space. The patient suffered from acute respiratory 
distress syndrome and had to be intubated. He eventually died from progression 
of respiratory failure. While there seems to be a temporal association, the 
causality is uncertain.
6- In Hamada10 paper, a 84 years old male with idiopathic pulmonary fibrosis, on 
home oxygen and hypercapnic respiratory failure developed a spontaneous 
pneumothorax. A chest tube was inserted, and 400 mL of dextrose 50% 
administered into the pleural space. Immediate pain and respiratory failure 
occurred. It was recommended for the patient to be intubated, but the family 
refused. The patient died 1 week later from progression of respiratory failure.
In the case of Patient 1, the death seems to be related to a nosocomial pneumonia and 
not from the intervention. Patient 2 had multiple attempts at pleurodesis with various 
agents (OK-432, blood, minocycline) before dextrose was tried. This is not the type of 
intervention planned in the current proposed study. Patient 3 seemed to have an acute 
reaction to dextrose 50%. The volume administered is twice the maximum dose we are 
planning to use.






It is hypothesized that the value of the information gained by performing this study will 
allow health care providers to have another option when comes the time to offer a 
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patient chemical pleurodesis (instead of offering talc, thoracic surgeons or respirologists 
will have the option of administering hypertonic glucose.
2.3.2 KNOWN POTENTIAL BENEFITS
After pulmonary resection, air leak is one of the most common complications arising 
from lung parenchyma at sites of division of adhesions, fissure dissection or lung 
retraction for exposure. A chest tube inserted at the end of the procedure will drain any 
ongoing air-leak allowing the underlying lung to re-expand. 
Patients who have an air leak on post-operative day 2 typically are typically offered 
observation, hoping the air leak will seal by itself. However, previous work showed that 
a significant number of patients who still leak on POD2 will have a prolonged air leak 
(more than 5 days), and then will be typically offered one of 3 options: 
1- waiting a longer period of time before removing the chest tube, with possibly 
discharging the patient home with a small one way valve if the lung stays well inflated, 
hoping the leak will have stopped at the next outpatient visit
2- injection of a sclerosing agent (such as talc) into the pleural space hoping the leak 
will stop
3- reoperation, hoping we can stop the leak 
It is known in the thoracic surgery literature that the longer a leak persists, the more 
likely the patient may suffer from an infection of the pleural space. Other complications 
such as catheter-related discomfort, arrhythmia or deep vein thrombosis could 
potentially be attributed to prolonged length of stay.
Reports have shown some efficacy in inducing pleurodesis. Participants to the study will 
therefore potentially be able to be discharged home sooner, have their chest tube 
removed sooner (leading to pain relief), and because the leak would stop earlier, there 
is a hypothetic benefit in reducing the risk of post-operative infectious complications18.
In addition, the worldwide current standard of practice to treat post-operative air leaks is 
typically to perform bedside chemical pleurodesis. A talc slurry is the most commonly 
used agent. A 2016 systematic review from Cochrane33 revealed that a wide range of 
agents are used to induce pleurodesis, including tetracycline (antibiotic), doxycycline 
(antibiotic), mepacrine (anti-malarial drug), bleomycine (chemotherapy agent), 
doxorubicin (chemotherapy agent), proviodine (antiseptic agent), OK-432 (inactivated 
preparation of Streptococcus pyogenes), C. parvum (bacteria), interferon 
(immunomodulating agent), chlormethine (chemotherapy agent), mitoxantrone 
(chemotherapy agent), and triethylenethiophosphoramide (chemotherapy agent). They 
all have various risk of toxicity, and a simpler agent such as dextrose could possibly 
provide similar efficacy with a better safety profile.
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3 OBJECTIVES AND PURPOSE
Objective: To define the most appropriate safe dose of D50 to heal air leaks in patients 
that have undergone lung resection surgery (Phase I study).
Hypothesis: In patients with a postoperative air leak following lung resection, the 
bedside administration of D50 into the pleural space on postoperative day 2 is safe 
(Phase I trial).
4 STUDY DESIGN AND ENDPOINTS
4.1 DESCRIPTION OF THE STUDY DESIGN
In this single-arm, phase I, single-center trial, patients with air leak on postoperative day 
2 following lung surgery will be invited to participate in the study. The precise definition 
of air leak is found in 4.2.2. The solution to be used as pleurodesis agent will consist of 
sterile 50% Glucose to be injected into the chest tube following the administration of 20 
mL of 1% lidocaine. The glucose solution is manufactured and marketed by Pfizer 
00037974) The agent comes in pre-filled 50 mL syringes (AnsyrTM II Syringe, product 
code 07517001), 25 g/50 mL.. Twenty-four hours after the intervention, if there is an air 
leak cessation (defined in 4.2.2), chest tube removal will be considered by the surgical 
team. However, if an air leak is still present, no further intervention will be planned. The 
exact time of cessation of air leak, time of chest tube removal, date of discharge, and 
any adverse events will be prospectively recorded. The volume of D50 administered is 
incremental and will follow a rule-based escalation, 3+3 design63: 3 patients will have a 
set dose, and if there are no dose-limiting toxicities (cf 6.1.7) or less than 2 moderate 
toxicties, the next group of 3 patients will go up one increment following review from the 
study safety committee to insure the acceptability of the treatment according to its side 
effects. The safety committee will meet on a monthly basis to review adverse events. 
The empiric increments will be 50 mL, 100 mL, 150 mL, and 200 mL. Therefore, a 
maximum of 12 patients will have to be enrolled. 
4.2 STUDY ENDPOINTS
4.2.1 PRIMARY ENDPOINT
The primary outcome of the Phase I study will be safety as defined by the lack of a 
grade 3, 4, or 5 adverse event at any given D50 volume according to the CTCAE v4.064.
4.2.2 SECONDARY ENDPOINTS
Secondary outcomes include the persistence of the air leak at 24h, 48h and 72h 
following the intervention, the pain score and point-of-care glucose measurement at 
baseline, 1h, 3h, 6h and 24h after the intervention, the pain level using a visual analog 
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scale at 1h, 3h, 6h, and 24h after intervention, the output from the chest tube during the 
first 24h after the intervention, the length of hospital stay, the duration of chest tube 
drainage, the need to discharge the patient with a one-way valve, the need for an 
additional chest tube insertion, the increase in supplemental oxygen requirements, the 
air leak rate, and the post-operative morbidity. In addition, patient analgesia 
consumption will be monitored, including the type of analgesia and the route of 
administration until the earliest between discharge day versus post-operative day 5. 
Also, the need for an intervention to address hyperglycemia will be monitored, including 
what type of intervention (insulin administration?) and the length of intervention. All of 
the above outcomes will be measured until post-operative day 5, infectious adverse 
events will be recorded until 2 weeks post-op. The recurrence of an air leak at 60 days 
will also be monitored.
Definition of air leak
The presence of an air leak using the Medela ThopazTM digital system is defined as an 
air leak equal or more than 40 mL/min for at least 1 hour during the last 12 hours if the 
tube is on suction, or equal or more than 20 mL/min for at least 1 hour during the last 12 
hours if the tube is on gravity mode.
Definition of cessation of air leak
An air leak has stopped if there was no record of sustained air leak (1 hour or more) of 
40 mL/min or more for the last 12 hours if the tube is on suction, or equal or more than 
20 mL/min for at least 1 hour during the last 12 hours if the tube is on gravity mode.
5 STUDY ENROLLMENT AND WITHDRAWAL
5.1 PARTICIPANT INCLUSION CRITERIA
In order to be eligible to participate in this study, an individual must meet all of the 
following criteria:
1. 18 years old or older
2. Lung resection is a wedge, segmentectomy, lobectomy or bilobectomy
3. Procedure performed by video-assisted thoracic surgery, or by thoracocomy
4. Presence of an air leak on the digital draining system on POD#2
5.2 PARTICIPANT EXCLUSION CRITERIA
An individual who meets any of the following criteria will be excluded from participation 
in this study: 
1. Large air leak arbitrarily defined as more than 1000 mL/min
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2. Allergy to local anesthetics
3. Hemodynamic instability
4. Untreated coronary artery disease
5. Need for respiratory support
6. Any other early post-operative complication
7. Immunity disorder
8. Large fluid output arbitrarily defined as more than 500 mL in the last 12 hours
9. Inability to give consent
10.Fasting glucose 14 mmol/L the morning of the intervention (arbitrarily chosen cut-off 
11.Endocrinology service not available to co-manage patients with either diabetes, or a 
fasting blood glucose 7 mmol/L, or HbA1c > 6.5%
12. Postoperative evidence of an active thoracic (lung or pleura) infection with SIRS (2 
or more of temperature > 38, heart rate > 90, respiratory rate > 20, WBC > 12)
5.3 STRATEGIES FOR RECRUITMENT AND RETENTION
On post-operative day 1, if the patient has an air leak as evaluated by the circle of care 
(thoracic surgery residents), s/he will be approached to assess whether s/he would be 
interested to participate in a study to treat air leaks. If the patient seems interested, the 
PI, co-investigator or the research coordinator will obtain consent. 
All lung resections in London, Ontario are performed in Victoria Hospital, and all the 
members of the Division of Thoracic Surgery, along with residents/nurse practitioners 
will be made aware of the existence of this study and the details.
5.4 PARTICIPANT WITHDRAWAL OR TERMINATION
5.4.1 REASONS FOR WITHDRAWAL OR TERMINATION
Participants are free to withdraw from participation in the study at any time upon 
request. All data collected up until withdrawal of consent will be kept and analyzed, but 
study if:
the participant meets an exclusion criterion (either newly developed or not 
previously recognized) that precludes further study participation
if the patient meets criteria mentioned in sections 5.5 or 8.5
5.4.2 HANDLING OF PARTICIPANT WITHDRAWALS OR TERMINATION
In this Phase I trial, we aim to capture adverse events, serious adverse events, and 
unanticipated problems. The intervention will happen only once and then the follow-up 
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is short (a few days). It would be unlikely to have participants withdrawing from the 
study or be terminated. 
If the study is prematurely terminated, participants will not be replaced.
If the study is not prematurely terminated, but the participant voluntarily withdraws from 
participation in the study, this subject will be replaced by approaching the next available 
patient who would satisfy inclusion and exclusion criteria as outlined in sections 5.1 to 
5.3.
5.5 PREMATURE TERMINATION OR SUSPENSION OF STUDY
The study will be stopped entirely due to safety concern if any grade 4 or 5 (death) 
adverse events according to the Common Terminology Criteria for Adverse Events 
(CTCAE) v 4.0 occurs, or if the patient is transferred to the intensive care unit (ICU) for 
any condition thought to be secondary to the intervention, or if the patient experiences 
pain (8/10 or more on visual analog scale) immediately after the intervention not 
relieved by oral or subcutaneous analgesia.
6 STUDY AGENT
6.1 STUDY AGENT AND CONTROL DESCRIPTION
6.1.1 ACQUISITION
The study agent is manufactured and marketed by 
-
filled 50 mL syringes (AnsyrTM II Syringe, product code 07517001), 25 g/50 mL. It will be 
acquired from the hospital pharmacy.
6.1.2 FORMULATION, APPEARANCE, PACKAGING, AND LABELING
The agent comes in pre-filled 50 mL syringes (AnsyrTM II Syringe). The solution is clear.
Please refer to the product brochure.
6.1.3 PRODUCT STORAGE AND STABILITY
Product should be stored between 20 to 25°C. Protect from freezing and excessive 
heat. 
Parenteral drug products should be inspected visually for particulate matter and 
discolouration prior to administration, whenever solution and container permit. 
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Do not use unless solution is clear and container or seal intact. Discard if it contains a 
precipitate. Single-use; discard unused portion. 
Please refer to the product brochure.
6.1.4 PREPARATION
The drug comes in pre-filled syringe. There is no preparation needed. In cases of 
volume superior to 50 mL (i.e. 100 mL, 150 mL or 200 mL), multiple syringes may have 
to be used.
6.1.5 DOSING AND ADMINISTRATION
The volume of Dextrose 50% administered is incremental and will follow a rule-based 
escalation, 3+3 design: 3 patients will have a set dose, and if there are no dose-limiting 
toxicities or less than 2 moderate toxicities (cf. 6.1.7), the next group of 3 patients will go 
up one increment following review from the study safety committee to insure the 
acceptability of the treatment according to its side effects. The safety committee will 
meet on a monthly basis to review adverse events. The empiric increments will be 50 
mL, 100 mL, 150 mL, and 200 mL. Therefore, a maximum of 12 patients will have to be 
enrolled.
6.1.6 ROUTE OF ADMINISTRATION
The route of administration will be intra-pleural through the chest tube already in place. 
The chest tube tubing will be disinfected, and then the solution injected into the tube. 
The tubing is kept elevated 50 cm above the chest of the patient in order to promote 
movement of the solution into the chest, and not into the digital drain device. The tube 
will not be clamped as there is an air leak, and clamping the tube may induce a tension 
pneumothorax (lung collapse).
6.1.7 STARTING DOSE AND DOSE ESCALATION SCHEDULE
Each participant will receive one dose only. The volume given will not be the same for 
all participants. We will start with 3 patients receiving 50 mL, then 3 other patients 
receiving each 100 mL, and so forth until reaching 200 mL after a total of 12 
participants.
Dose limiting toxicities include any grade 4 or grade 5 (death) adverse events according 
to the Common Terminology Criteria for Adverse Events (CTCAE) v 4.0., in addition of 
the following:
1. Transfer to the ICU for any cause presumed to be related to the intervention
2. Pain score equal or more than 8/10 in visual analog scale not relieved by oral or 
subcutaneous analgesia 
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Moderate toxicities include all grade 3 toxicities presumed to be related to the 
intervention, in addition of the following:
1. Very high chest tube output, arbitrarily defined as > 1 L/12 hours
6.1.8 DOSE ADJUSTMENTS/MODIFICATIONS/DELAYS
Adjustments or modifications of dose is not anticipated.
6.1.9 DURATION OF THERAPY
Data will be recorded and tracked until post-operative day 5 or until discharge. A follow-
up visit will happen at post-operative day 14 to monitor for infectious adverse events.
6.1.10 TRACKING OF DOSE
The dose is administered by the circle of care (thoracic surgery residents). It will also be 
listed in the MAR (Medication Administration Record).
6.2 STUDY AGENT ACCOUNTABILITY PROCEDURES
The study agent will be sent to the Thoracic Surgery Ward as for any other drug. Upon 
reception to the ward, it will be administered.
7 STUDY PROCEDURES AND SCHEDULE
7.1 STUDY PROCEDURES/EVALUATIONS
7.1.1 STUDY SPECIFIC PROCEDURES
If a participant is enrolled into this trial, s/he will require the following study procedures:
Point of care glycemia evaluation before the intervention, 1 hour after the 
intervention, 3 hours after the intervention, 6 hours after the intervention, and 24 
hours after the intervention
Should the glycemia rises above 11 mmol/L, co-management from an endocrinologist 
and monitoring will be requested.
7.1.2 STANDARD OF CARE STUDY PROCEDURES
If a participant is enrolled into this trial, s/he will not require any other standard of care 
procedure.
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7.2 LABORATORY PROCEDURES/EVALUATIONS
7.2.1 CLINICAL LABORATORY EVALUATIONS
The only laboratory evaluation required as part of this study is point-of-care glycemia.
7.2.2 OTHER ASSAYS OR PROCEDURES
N/A






On post-operative day 1, if the patient has an air leak as evaluated by the circle of care 
(thoracic surgery residents), s/he will be approached to assess whether s/he would be 
interested to participate in a study to treat air leaks. If the patient seems interested, the 
PI, co-investigator or the research coordinator will obtain consent.
POD#1
During morning rounds, the thoracic surgery residents assess whether there is 
an active air leak or not
The circle of care will evaluate all inclusion and exclusion criteria, and, if 
appropriate, will approach the patient to enquire if he would be interested in 
participating in a study to treat post-operative air leaks
if the patient is interested, either the PI, a co-investigator or the study coordinator 
will approach the patient, will explain the study and answer questions
7.3.2 ENROLLMENT/BASELINE
POD#2
If there is still an air leak during morning rounds, informed consent will be 
obtained from the investigators if the patient is still interested with pursuing with 
the trial
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a baseline point-of-care glycemia will be performed at that time
7.3.3 FOLLOW-UP
All participants are hospitalized. They are followed up at least twice daily if inpatients. 
All the outcomes are recorded until post-operative day 5 (or 72 hours after the 
intervention), with the exception of infectious adverse events that can arise on a 
delayed fashion. Patients will therefore be evaluated on POD#14 for that reason in an 
outpatient setting (Thoracic Surgery clinic).
7.3.4 FINAL STUDY VISIT
The final study visit will be POD#14 (+/- 2 days to accommodate for statutory 
holidays/weekends). Adverse events will be recorded.
7.3.5 EARLY TERMINATION VISIT
Evaluation of adverse events are performed if there is an early termination visit 
(although unlikely).
7.3.6 UNSCHEDULED VISIT
The patients are instructed prior to discharge to let the Thoracic Surgery team know if 
any adverse event occur. They are given instructions as to where/who to call during 
weekdays hours and after-hours.




















7.4 CONCOMITANT MEDICATIONS, TREATMENTS, AND PROCEDURES
N/A
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7.5 JUSTIFICATION FOR SENSITIVE PROCEDURES
N/A
7.5.1 PRECAUTIONARY MEDICATIONS, TREATMENTS, AND PROCEDURES
N/A
7.6 PROHIBITED MEDICATIONS, TREATMENTS, AND PROCEDURES
N/A
7.7 PROPHYLACTIC MEDICATIONS, TREATMENTS, AND PROCEDURES
Intrapleural lidocaïne 1%, 20 mL will be administered before hypertonic dextrose 
administration
7.8 RESCUE MEDICATIONS, TREATMENTS, AND PROCEDURES
Pain, if any, will be managed as part of our standard post-operative order set 
(analgesics).
Fever, if any, will be investigated. Fever, defined as an oral temperature equal or 
superior to 38 degrees Celsius, will require performance of blood and pleural fluid 
cultures. Acetaminophen administration will be avoided in order to not mask an 
underlying infection. Acetaminophen will be administered only if absolutely necessary. 
The reason for administration, the start time and date, the stop time and date, and the 
total dose of acetaminophen administered will be recorded.
Hyperglycemia, if any, will be managed as part of our standard post-operative order set 
(insulin scale if needed).
Desaturation, if any, will be managed as part of our standard post-operative order set 
(supplemental oxygen).
If the air leak fails to heal despite dextrose administration, the study participant will not
be receiving more dextrose. It will be up to the Most Responsible Physician to use 
his/her clinical judgement and perform one of these 3 options:
1. inject another intra-pleural agent such as talc (agent currently used in clinical 
practice)
2. wait a few more days, and possibly discharge the patient home with a tube still in 
place connected to a one-way valve
3. on very rare circumstances, patients may have to be re-operated to surgically 
address the leak
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7.9 PARTICIPANT ACCESS TO STUDY AGENT AT STUDY CLOSURE
N/A
8 ASSESSMENT OF SAFETY
8.1 SPECIFICATION OF SAFETY PARAMETERS
8.1.1 DEFINITION OF ADVERSE EVENTS (AE)
Adverse event means any untoward medical occurrence associated with the use of an 
intervention in humans, whether or not considered intervention-related (21 CFR 312.32 
(a)).
8.1.2 DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)
Serious adverse event or serious suspected adverse reaction. An AE or suspected 
adverse reaction is considered "serious" if, in the view of either the investigator or
sponsor, it results in any of the following outcomes: death, a life-threatening adverse 
event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or 
significant incapacity or substantial disruption of the ability to conduct normal life 
functions, or a congenital anomaly/birth defect. Important medical events that may not 
result in death, be life-threatening, or require hospitalization may be considered serious 
when, based upon appropriate medical judgment, they may jeopardize the patient or 
subject and may require medical or surgical intervention to prevent one of the outcomes 
listed in this definition. Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or 
convulsions that do not result in inpatient hospitalization, or the development of drug 
dependency or drug abuse. 
8.1.3 DEFINITION OF UNANTICIPATED PROBLEMS (UP)
OHRP considers unanticipated problems involving risks to participants or others to 
include, in general, any incident, experience, or outcome that meets all of the following 
criteria: 
Unexpected in terms of nature, severity, or frequency given (a) the research 
procedures that are described in the protocol-related documents, such as the 
IRB-approved research protocol and informed consent document; and (b) the 
characteristics of the participant population being studied; 
Related or possibly related to partici
means there is a reasonable possibility that the incident, experience, or outcome 
may have been caused by the procedures involved in the research); and 
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Suggests that the research places participants or others at a greater risk of harm 
(including physical, psychological, economic, or social harm) than was previously 
known or recognized.
This study will use the OHRP definition of UP. 
8.2 CLASSIFICATION OF AN ADVERSE EVENT
8.2.1 SEVERITY OF EVENT
For AEs not included in the protocol defined grading system, the following guidelines 
will be used to describe severity. 
Mild Events require minimal or no treatment and do not interfere with the 
Moderate Events result in a low level of inconvenience or concern with the 
therapeutic measures. Moderate events may cause some interference with 
functioning. 
Severe
systemic drug therapy or other treatment. Severe events are usually potentially 
life-threatening or incapacitating. 
8.2.2 RELATIONSHIP TO STUDY AGENT
For all collected AEs, the clinician who examines and evaluates the participant will 
poral relationship and his/her clinical 
judgment. The degree of certainty about causality will be graded using the categories 
below. 
Definitely Related There is clear evidence to suggest a causal relationship, 
and other possible contributing factors can be ruled out. The clinical event, 
including an abnormal laboratory test result, occurs in a plausible time 
relationship to drug administration and cannot be explained by concurrent 
disease or other drugs or chemicals. The response to withdrawal of the drug
(dechallenge) should be clinically plausible. The event must be pharmacologically 
or phenomenologically definitive, with use of a satisfactory rechallenge procedure 
if necessary. 
Probably Related There is evidence to suggest a causal relationship, and the 
influence of other factors is unlikely. The clinical event, including an abnormal 
laboratory test result, occurs within a reasonable time after administration of the 
drug, is unlikely to be attributed to concurrent disease or other drugs or 
chemicals, and follows a clinically reasonable response on withdrawal 
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(dechallenge). Rechallenge information is not required to fulfill this definition. 
Possibly Related There is some evidence to suggest a causal relationship 
(e.g., the event occurred within a reasonable time after administration of the trial 
medication). However, other factors may have contributed to the event (e.g., the 
n, other concomitant events). Although an AE may 
Unlikely to be related A clinical event, including an abnormal laboratory test 
result, whose temporal relationship to drug administration makes a causal 
relationship improbable (e.g., the event did not occur within a reasonable time 
after administration of the trial medication) and in which other drugs or chemicals 
clinical condition, other concomitant treatments). 
Not Related The AE is completely independent of study drug administration, 
and/or evidence exists that the event is definitely related to another etiology. 
There must be an alternative, definitive etiology documented by the clinician. 
8.2.3 EXPECTEDNESS
An AE will be considered unexpected if the nature, severity, or frequency of the event is 
not consistent with the risk information previously described for the study agent. For 
example, it is expected for intrapleural hypertonic glucose to produce some degree of 
chest discomfort, low grade fever, and sometimes self-resolving dyspnea.
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND 
FOLLOW-UP
The occurrence of an AE or SAE may come to the attention of study personnel during 
study visits and interviews of a study participant presenting for medical care, or upon 
review by a study monitor.
All AEs including local and systemic reactions not meeting the criteria for SAEs will be 
captured on the appropriate data report form. Information to be collected includes event 
, relationship to study 
product (assessed only by those with the training and authority to make a diagnosis), 
and time of resolution/stabilization of the event. All AEs occurring while on study must 
be documented appropriately regardless of relationship. All AEs will be followed to 
adequate resolution. 
Any medical condition that is present at the time that the participant is screened will be 
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condition deteriorates at any time during the study, it will be recorded as an AE. UPs will 
be recorded in the data collection system throughout the study. 
Changes in the severity of an AE will be documented to allow an assessment of the 
duration of the event at each level of severity to be performed. AEs characterized as 
intermittent require documentation of onset and duration of each episode. 
The PI will record all reportable events with start dates occurring any time after informed 
consent is obtained until 7 (for non-serious AEs) or 60 days (for SAEs) after the last day 
of study participation. At each study visit, the investigator will inquire about the 
occurrence of AE/SAEs since the last visit. Events will be followed for outcome 
information until resolution or stabilization. 
8.4 REPORTING PROCEDURES
8.4.1 ADVERSE EVENT REPORTING
Study adverse events will be logged into the institutional data collection program 
(REDCap). They will be disclosed to the Data Safety Monitoring Board on a monthly 
basis.
8.4.2 SERIOUS ADVERSE EVENT REPORTING
The study clinician will complete a SAE Form within the following timelines: 
All deaths and immediately life-threatening events, whether related or unrelated, 
will be recorded on the SAE Form and submitted to the study sponsor and DSMB 
within 24 hours of site awareness. See Section 1, Key Roles for contact 
information. 
Other SAEs regardless of relationship, will be submitted to the study sponsor and 
DSMB within 72 hours of site awareness. 
All SAEs will be followed until satisfactory resolution or until the site investigator deems 
the event to be chronic or the adherence to be stable. Other supporting documentation 
of the event may be requested by the study sponsor and should be provided as soon as 
possible.
The study sponsor will be responsible for notifying Health Canada of any unexpected 
fatal or life-threatening suspected adverse reaction as soon as possible but in no case 
later than 7 calendar days after the sponsor's initial receipt of the information. 
8.4.3 UNANTICIPATED PROBLEM REPORTING
Incidents or events that meet the OHRP criteria for UPs require the creation and 
comple
PLUG-1 Version 2.05
Protocol MQRM711                                                                                    11 July 2019
Clinical Trial Protocol v2.05 20190711 21
to their IRB and to the study sponsor and DSMB. The UP report will include the 
following information: 
ame, and the 
IRB project number; 
A detailed description of the event, incident, experience, or outcome; 
An explanation of the basis for determining that the event, incident, experience, 
or outcome represents an UP; 
A description of any changes to the protocol or other corrective actions that have 
been taken or are proposed in response to the UP.
To satisfy the requirement for prompt reporting, UPs will be reported using the following 
timeline: 
UPs that are SAEs will be reported to the IRB and to the study sponsor and 
DSMB within 72 hours of the investigator becoming aware of the event. 
Any other UP will be reported to the IRB, to the study sponsor and to the DSMB 
within 7 days of the investigator becoming aware of the problem. 
All UPs should be reported to appropriate institutional officials (as required by an 
he supporting agency head (or 
problem from the investigator. 
8.4.4 EVENTS OF SPECIAL INTEREST
N/A
8.4.5 REPORTING OF PREGNANCY
N/A
8.5 STUDY HALTING RULES
Administration of study agent will be halted if on a single patient 2 grade 3 AEs 
grade 4 or grade 5 (SAE) is reported. The Data Coordinating Center will notify the study 
sponsor and investigators immediately and enrollment screens will stop accepting new 
study participants. The study sponsor will inform the DSMB members within 24 hours of 
this occurrence and will provide the DSMB with AE listing reports. The DSMB will
convene an ad hoc meeting by teleconference or in writing as soon as possible. The 
DSMB will provide recommendations for proceeding with the study to the study 
sponsor/Health Canada. The study sponsor will inform Health Canada of the temporary 
halt and the disposition of the study.
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8.6 SAFETY OVERSIGHT
Safety oversight will be under the direction of a DSMB composed of individuals with the 
appropriate expertise, including lung and pleural physiology. Such individuals would be 
physicians specialized in thoracic surgery, anesthesiology, respirology and 
endocrinology. The DSMB will be independent from the study investigators. The DSMB 
will meet at least monthly to assess safety data on the study. The first meeting will take 
place before the first patient is enrolled. The DMSB will operate under the rules of an 
approved charter that will be written and reviewed at the organizational meeting of the 
DSMB. At this time, each data element that the DSMB needs to assess will be clearly 
defined. The DSMB will provide its input to the principal investigator and co-investigator. 
9 CLINICAL MONITORING
Clinical site monitoring is conducted to ensure that the rights and well-being of human 
subjects are protected, that the reported trial data are accurate, complete, and 
verifiable, and that the conduct of the trial is in compliance with the currently approved 
protocol/amendment(s), and with applicable regulatory requirement(s). 
One of the DSMB member will conduct a single, on-site, random monitoring 
evaluation 
Independent audits will not be conducted 
Each clinical site will perform internal quality management of study conduct, data 
collection, documentation and completion. An individualized quality management 
plan wi
10 STATISTICAL CONSIDERATIONS
10.1 STATISTICAL AND ANALYTICAL PLANS






10.4 DESCRIPTION OF STATISTICAL METHODS
10.4.1 GENERAL APPROACH
Our data will be mostly descriptive in nature. Data will be presented using percentages, 
means (with standard deviations), median, range.
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10.4.2 ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)
We do not anticipate any missing data. The data will be descriptive.
10.4.3 ANALYSIS OF THE SECONDARY ENDPOINT(S)
We do not anticipate any missing data. The data will be descriptive. Cf Section 10.4.11, 
Exploratory Analyses.
10.4.4 SAFETY ANALYSES
The adverse events are graded using the CTCAE v.4.0. Information reported about 
each AE are: 
start time and date




AEs will be PI reported.
All grade 4 or grade 5 AEs are considered SAEs.
10.4.5 ADHERENCE AND RETENTION ANALYSES
N/A
10.4.6 BASELINE DESCRIPTIVE STATISTICS
Planned descriptive statistics include means and rate for demographics (age, gender, 
comorbidities), ASA, conversion to thoracotomy, VATS/thoracotomy, type of lung 
resection, presence of an air leak pre-op, mean glycemia increase over time, mean pain 
increase over time, rate of resolution of air leak 24 hours, 48 hours and 72 hours after 
the intervention, mean length of stay, mean chest tube output over 24 hours after the 
intervention, mean duration of chest tube drainage, rate of patients needing to be 
discharged on a one-way valve, rate of patients requiring insertion of another tube, need 
for an increase in oxygen requirements after the intervention, rate of patients being 
discharged with home oxygen, mean air leak rate 24 hours, 48 hours, and 72 hours 
post-intervention.
10.4.7 PLANNED INTERIM ANALYSES
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10.4.7.1 SAFETY REVIEW
Please refer to Section 5.5, Premature Termination or Suspension of Study, and to 
Section 8.5 Study Halting Rules.
No statistical analyses will be required for safety review.
10.4.7.2 EFFICACY REVIEW
N/A
10.4.8 ADDITIONAL SUB-GROUP ANALYSES
Because of the relatively small sample size, no sub-group analyses will be performed.
10.4.9 MULTIPLE COMPARISON/MULTIPLICITY
N/A
10.4.10 TABULATION OF INDIVIDUAL RESPONSE DATA
N/A
10.4.11 EXPLORATORY ANALYSES
If dramatic absolute differences are noted between different volumes of D50, we may 
perform exploratory analyses (comparison between mean chest tube output at 24 hours 
for instance between participants who received 50 mL versus 200 mL).
10.5 SAMPLE SIZE
For this phase I trial, we did not calculate a simple size as we will use a rule-based 
escalation, 3+3 design63. We will have 3 patients receiving each one administration of 
the following volume of D50: 50 mL, 100 mL, 150 mL, 200 mL. We will require a total of 
12 patients.
10.6 MEASURES TO MINIMIZE BIAS
10.6.1 ENROLLEMENT/RANDOMIZATION/MASKING PROCEDURES
The research coordinator will obtain consent and our nurse practitioner or physician 
assistant will administer the dextrose. Assessment of adverse events will be performed 
by the residents working in the thoracic surgery team and be logged in an institutional 
secured database (REDCap). These residents are not investigators. The investigators 
will therefore be blinded, thus reducing potential bias.
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Ultimately, we are planning to perform a Phase III which would be blinded to avoid 
observer bias.
We will reduce selection bias by considering everyone for the study and approaching 
them to participate. 
10.6.2 EVALUATION OF SUCCESS OF BLINDING
We will ask members of the team if they knew what dose if any the patient received.
10.6.3 BREAKING THE STUDY BLIND/PARTICIPANT CODE
N/A
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS
Data collected pertaining to the study will be stored on our institutional database 
(REDCap), approved by Lawson Health Research Institute.
The principal investigator, co-investigators, research coordinator, Western University 
Health Sciences Research Ethics Board, and Lawson Quality Assurance and Education 
Program will have access to this data.
12 QUALITY ASSURANCE AND QUALITY CONTROL
Quality control procedures will be implemented beginning with the data entry system 
and data quality control checks that will be run on the database will be generated. Any 
missing data or data anomalies will be communicated for clarification/resolution. 
The monitors will verify that the clinical trial is conducted and data are generated, 
documented (recorded), and reported in compliance with the protocol. 
The investigational site will provide direct access to all trial related sites, source 
data/documents, and reports for the purpose of monitoring and auditing by the sponsor, 
and inspection by local and regulatory authorities. 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS
13.1 ETHICAL STANDARD
The investigator will ensure that this study is conducted in full conformity with 
Regulations for the Protection of Human Subjects of Research codified in 45 CFR Part 
46, 21 CFR Part 50, 21 CFR Part 56, and/or the ICH E6.
PLUG-1 Version 2.05
Protocol MQRM711                                                                                    11 July 2019
Clinical Trial Protocol v2.05 20190711 26
13.2 INSTITUTIONAL REVIEW BOARD
The protocol, informed consent form(s), recruitment materials, and all participant 
materials will be submitted to the IRB for review and approval. Approval of both the 
protocol and the consent form must be obtained before any participant is enrolled. Any 
amendment to the protocol will require review and approval by the IRB before the 
changes are implemented to the study. All changes to the consent form will be IRB 
approved; a determination will be made regarding whether previously consented 
participants need to be re-consented. 
13.3 INFORMED CONSENT PROCESS
13.3.1 CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS 
PROVIDED TO PARTICIPANTS
Consent forms describing in detail the study agent, study procedures, and risks are 
given to the participant and written documentation of informed consent is required prior 
to starting intervention/administering study product. The following consent materials are 
submitted with this protocol:
Letter of information & Consent
13.3.2 CONSENT PROCEDURES AND DOCUMENTATION
Informed consent is a process that is initiated prior to the
Extensive discussion of risks and possible benefits of participation will be provided to 
the participants and their families. Consent forms will be IRB-approved and the 
participant will be asked to read and review the document. The investigator will explain 
the research study to the participant and answer any questions that may arise. All 
participants will receive a verbal explanation in terms suited to their comprehension of 
the purposes, procedures, and potential risks of the study and of their rights as research 
participants. Participants will have the opportunity to carefully review the written consent 
form and ask questions prior to signing. The participants should have the opportunity to 
discuss the study with their surrogates or think about it prior to agreeing to participate. 
The participant will sign the informed consent document prior to any procedures being 
done specifically for the study. The participants may withdraw consent at any time 
throughout the course of the trial. A copy of the informed consent document will be 
given to the participants for their records. The rights and welfare of the participants will 
be protected by emphasizing to them that the quality of their medical care will not be 
adversely affected if they decline to participate in this study. 
13.4 PARTICIPANT AND DATA CONFIDENTIALITY
Participant confidentiality is strictly held in trust by the participating investigators, their 
staff, and the sponsor. This confidentiality is extended to cover the clinical information 
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relating to participants. Therefore, the study protocol, documentation, data, and all other 
information generated will be held in strict confidence. No information concerning the 
study or the data will be released to any unauthorized third party without prior written 
approval of the sponsor. 
The study monitor, other authorized representatives of the sponsor, representatives of 
the IRB may inspect all documents and records required to be maintained by the 
investigator, including but not limited to, medical records (hospital) and pharmacy 
records for the participants in this study. The clinical study site will permit access to 
such records. 
The study partici
internal use during the study. At the end of the study, all records will continue to be kept 
in a secure location for as long a period as dictated by local IRB and Institutional 
regulations. A master linking log with identifiers will be stored separately from the study 
data.
Study participant research data, which is for purposes of statistical analysis and 
scientific reporting, will be kept at the study center. Individual participants and their 
research data will be identified by a unique study identification number. The study data 
entry and study management systems used by the clinical site and by research staff will 
be secured and password protected. At the end of the study, all study databases will be 
de-identified and archived. 
13.4.1 RESEARCH USE OF STORED HUMAN SAMPLES, SPECIMENTS OR DATA
Storage: Access to stored data will be limited using access to selected
individuals and password protected. Data will be stored using codes assigned by
the investigators. Data will be kept in password-protected institutional database.
Only investigators will have access to the data.
Data will be tracked using by logging who electronically access them
o Disposition at the completion of the study: All stored consent forms will be
13.5 FUTURE USE OF STORED SPECIMENS
N/A
14 DATA HANDLING AND RECORD KEEPING
14.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES
Data collection is the responsibility of the clinical trial staff at the site under the 
supervision of the site PI. The investigator is responsible for ensuring the accuracy, 
completeness, legibility, and timeliness of the data reported. 
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All source documents should be completed in a neat, legible manner to ensure accurate 
interpretation of data. Black ink is required to ensure clarity of reproduced copies. When 
making changes or corrections the original entry will be crossed out with a single line, 
and initialed and date of the change will be recorded.
Clinical data (including AEs, concomitant medications, and expected adverse reactions 
data) and clinical laboratory data will be entered into REDCap, a 21 CFR Part 11-
compliant data capture system. The data system includes password protection and 
internal quality checks, such as automatic range checks, to identify data that appear 
inconsistent, incomplete, or inaccurate. 
14.2 STUDY RECORDS RETENTION
Study documents should be retained for a minimum of 25 years. No records will be 
destroyed without the written consent of the sponsor, if applicable. It is the responsibility 
of the sponsor to inform the investigator when these documents no longer need to be 
retained.
14.3 PROTOCOL DEVIATIONS
A protocol deviation is any noncompliance with the clinical trial protocol. The 
noncompliance may be either on the part of the participant, the investigator, or the study 
site staff. As a result of deviations, corrective actions are to be developed by the site 
and implemented promptly. 
It is the responsibility of the site to use continuous vigilance to identify and report 
deviations within 7 working days of identification of the protocol deviation, or within 7 
working days of the scheduled protocol-required activity. All deviations must be reported 
to Health Canada. Protocol deviations must be sent to the local IRB per their guidelines. 
The site PI/study staff is responsible for knowing and adhering to their IRB 
requirements. 
14.4 PUBLICATION AND DATA SHARING POLICY
The International Committee of Medical Journal Editors (ICMJE) member journals have 
adopted a clinical trials registration policy as a condition for publication. The ICMJE 
defines a clinical trial as any research project that prospectively assigns human subjects 
to intervention or concurrent comparison or control groups to study the cause-and-effect 
relationship between a medical intervention and a health outcome. Medical 
interventions include drugs, surgical procedures, devices, behavioral treatments, 
process-of-care changes, and the like. Health outcomes include any biomedical or 
health-related measures obtained in patients or participants, including pharmacokinetic 
measures and adverse events. The ICMJE policy requires that all clinical trials be 
registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by the 
National Library of Medicine. Other biomedical journals are considering adopting similar 
policies. The ICMJE does not review specific studies to determine whether registration 
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is necessary; instead, the committee recommends that researchers who have questions 
about the need to register err on the side of registration or consult the editorial office of 
the journal in which they wish to publish. 
15 STUDY ADMINISTRATION
15.1 STUDY LEADERSHIP
The Study Team will govern the conduct of the study. The Study Team will be 
composed of the principal investigator, co-investigator and research coordinator.
16 CONFLICT OF INTEREST POLICY
The independence of this study from any actual or perceived influence, such as by the 
pharmaceutical industry, is critical. Therefore, any actual conflict of interest of persons 
who have a role in the design, conduct, analysis, publication, or any aspect of this trial 
will be disclosed and managed. Furthermore, persons who have a perceived conflict of 
interest will be required to have such conflicts managed in a way that is appropriate to 
their participation in the trial. The study leadership has established policies and 
procedures for all study group members to disclose all conflicts of interest and will 
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APPENDIX
Version Date Significant Revisions
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and 7.8
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5.2, 7.1.1, 7.8, 8.3
2.04 10 July 2019 Clarification of Sections 7.8 and 8.6
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Appendix G
Letter of Information & Consent
Project Title: PLeurodesis Using hypertonic Glucose administration to treat 
post-operative air leaks following lung resection surgery 
(PLUG): Phase I trial. 
Principal Investigator: Richard Malthaner, MD MSc FRCSC FACS
Research Director, Division of Thoracic Surgery
London Health Sciences Centre 
Co-Investigators: Mehdi Qiabi, MD FRCSC
Funded by: UWO Internal Surgery Internal Research Fund
Introduction:
invited to participate in a research study. You are being asked to participate because you 
had a lung resection, and you are experiencing an air leak following your surgery. Before 
you decide to participate, it is important for you to understand why this study is being 
done what it will involve. Please take time to read the following information carefully 
and discuss it with your family and friends and/or your family doctor if you wish. There 
may be words of statements that you do not understand. Ask your study doctor or staff 
to explain anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part.
Before agreeing to participate in this study, it is important you know about the study. This 
document describes the purpose, procedures, benefits, discomforts and risks associated 
with this study, as well as your rights if you decide to participate in this study. 
Purpose of Study:
Many patients experience air leaks after having a lung resection. This may cause you to 
stay in the hospital for longer while this leak stops.
This clinical study will evaluate the feasibility and effectiveness of using a concentrated 
glucose (sugar) solution injected into the space between your chest wall and your lungs, 
to stop the leak.
Number of Participants:
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A total of 12 patients will be recruited.
Participation Eligibility:
You are eligible for the study if you have an air leak following your lung resection. That 
air leak needs to be persistent for 2 days after your surgery. Note that you will only be 
included if you have given your written consent to partake in the study.
Voluntary Participation:
Participation in this study is voluntary. You may refuse or agree to participate in the study. 
You may withdraw from the study at any moment without any effect on your future care. 
If you decide to withdraw from the study, the information that was collected before you 
leave the study will still be used to help answer the research question. No new information 
will be collected without your permission.
If you are not interested in participating in this study:
The standard of care is to wait until the leak stops on its own. It may take several days to 
several weeks. Sometimes, we let patients go home with their chest tube still in place 
attached to a one-way valve, and we reevaluate them in the clinic on a weekly basis. 
Unfortunately, there are patients whose leak does not heal on its own. It is hard to predict 
the duration of an air leak. In the case of a persistent air leak that does not heal on its 
own, we normally inject a product through the tube going into the chest called talc to 
create an inflammatory reaction and hope that it will stop the air leak. The longer the 
duration of air leak, the higher the risk of infection. It is therefore hoped that the leak is 
stopped as soon as possible. Rarely, patients may require a second surgery to address 
and stop the air leak.
Goal of the study:
The research procedure offered to you is to inject a solution with high concentration of 
sugar into the chest tube 2 days after the surgery if there is an air leak, hoping that the 
leak stops quickly. We are therefore offering you an intervention sooner than we usually 
would have. This intervention may or may not work.
You may choose not to participate in this study. This requires to keep the chest tube until 
the leak stops.
Your study doctor can tell you more about your condition and the possible benefits of the 
available treatments.
Be reassured that should you decide to refuse to participate in this study, the care you 
will receive will be unaffected.
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Study Procedure:
If you choose to take part in this study, between 50 millilitres and 200 millilitres of a 
solution of 50% glucose will be injected into your pleural space (the space between your 
chest wall and your lungs) the second day after the surgery. This is done after injecting a 
local anesthetic to numb your chest cavity (lidocaine). The injection will be administered 
through your chest tube, which is already in place. There will be no injection of talc.
Some studies have already shown that a volume between 180 milliliters and 200 milliliters 
seem to be effective and appears safe. However, these volumes were chosen arbitrarily. 
The aim of this study is to be confident that the dose administered to patients is safe. 
Each participant will receive only one injection of glucose at a defined volume. We will
start with a smaller amount (50 milliliters), and an independent group of physicians will 
analyze the data and potential associated adverse events. They have a list of criteria. If 
the dose is considered safe, we will increase the volume to 100 milliliters for the next 
group of participants. The same process will repeat until we reach a maximum volume of 
200 milliliters.
If you choose to take part in this study, you will be followed by a researcher who will 
monitor you for the duration of your air leak, the duration of chest drainage, the length of 
hospitalization, and the occurrence of complications or discomfort. 
Potential benefits associated with participation in this study:
If you agree to take part in this study, there may or may not be direct medical benefit to 
you. Your hospital stay and how long you require a chest tube may be reduced by this 
treatment. It may also prevent further air leak or lung collapse, decrease chest tube pain, 
and decrease post-operative complications.
Potential risks associated with participation in this study:
If you agree to participate in this trial, you may be at risk of potential side effects. You 
should discuss these with the study doctor. There are some side effects that cannot be 
predicted. These side effects are unlikely to happen.
Temporary increase in the blood sugar level (hyperglycemia), a condition that is
generally easily treated with no long-term consequences if monitored and treated
appropriately
Inflammation of the lung (pneumonitis) caused by the sugar-rich solution injected,
which is a serious but rare complication
Pain
Infection
All the information collected during the research project will remain strictly confidential to 
the extent provided by law although confidentiality cannot be guaranteed as there is a risk 
of breach of privacy.
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Should you become injured or ill as a result of participating in the study, all medical care 
will be provided to you at no cost.
Confidentiality:
The study investigators are committed to respecting your privacy. Any documents 
containing identifiable information will be stored in a locked cabinet at Victoria Hospital, 
accessible only to the research team. A unique study number will be assigned to your 
data. A list linking your study number with your initials and hospital identification number 
will stored on a password-protected computer on a secure network behind institutional 
firewalls at Victoria Hospital. All documentation will be destroyed 15 years after the 
ata retention policy. De-identified data will be 
entered in an institutional database protected by a firewall.
Qualified representatives of the following organizations may look at your medical/clinical 
study records at the site where these records are held, for quality assurance (to check 
that the information collected for the study is correct and follows proper laws and 
guidelines). 
Representatives of Lawson Quality Assurance Education Program
Representatives of the University of Western Ontario Health Sciences Research
Ethics Board that oversees the ethical conduct of this study
Compensation and Costs:
You will not be reimbursed for your participation in this study. There is no compensation 
to you in relation to this research study. 
Rights as a Participant:
You do not waive any legal right by signing this consent form.
If you have any questions about your rights as a research participant or the conduct of 
this study, you may contact the Patient Experience Office at LHSC at 
 or access the online form at:
Questions about the Study:
If you have questions about the study contact the principal investigator, Dr. Richard 
Malthaner at  or Deb Lewis, study coordinator at .
A copy of this letter of information & consent is for you to keep.
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Consent Form
This study has been explained to me and any questions I had have been answered.  I 
know that I may leave the study at any time. I agree to participate in the study.
____________________  ___________________   __________________
Print Name of Participant Signature of Participant   Date
My signature means that I have explained the study to the participant named above. I 
have answered all questions.
____________________ ___________________ __________________
Print Name of Person Signature     Date
Obtaining Consent
Was the participant assisted during the consent process? YES NO 
If YES, please check the relevant box and complete the signature space below: 
The person signing below acted as a translator for the participant during the consent 
process and attests that the study as set out in this form was accurately translated and 
has had any questions answered.
_____________________  ___________________   __________________
Print Name of Translator Signature Date    
_____________________
Language
The consent form was read to the participant. The person signing below attests that the 
study as set out in this form was accurately explained to, and has had any questions 
answered.
_____________________ ___________________   __________________
Print Name of Witness Signature Date    
_____________________








This is Patient #1 from Figure 5-A. Red line denotes when D50 was administered (43 
hours here). There are various points recorded with time in hours in the X-axis, and air 
leak rate in mL/min in the Y-axis. The area under the curve represents the volume of air. 
We can calculate this area under the curve by using the trapezoidal rule. The area of 
interest is chosen, here it is between the last recorded value before the red line (41
hours) up since the 17 hours mark, so the volume of the preceding 24 hours is 
calculated. In this situation, there is no recorded flow at 17 hours, but the air leak rate at 
16 and 19 hours are known. It is therefore possible to approximate the air flow rate at 17
hours.

The area under the curve is segmented in several trapezia. Each trapezius surface area 
(TSA) is calculated using the formula TSA = h(a + b)/2. The sum of each trapezius 





































































































































Example of RStudio code used to create the segmented regressions/interrupted time 




The terms (Glucose OR dextrose OR Glucose Solution, Hypertonic) AND (Pleurodesis 
OR pneumothorax OR pneumothoraces) were used on PubMed, Google Scholar and 
SCOPUS. Cochrane database was searched for the term 
There was 
no restriction on publication date range. Mr. David Le Sauvage, librarian at Western 
University, assisted with this search strategy. Two authors (M Qiabi, A Ednie) worked 
independently and screened available studies. The references of all relevant studies 
were manually assessed to avoid missing any available paper.
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administration to treat post-operative air leaks following lung resection surgery (PLUG): 
Phase I trial. Supervisor: Dr. Richard Malthaner, London, Ontario, Canada 
Specialized Training 
2019 POEM / ESD training, The Foundation for Surgical Innovation & Education, Foregut Surgery, 
POEM / ESD training, Portland, Oregon, United States 
2019 Interventional GI Endoscopy Advanced 
Course, IRCAD, Foregut Surgery, POEM / ESD training, Strasbourg, Bas-Rhin, France 
APPOINTMENTS
Academic Appointments 
2019 - present Assistant Professor, Department of Surgery, Division of Thoracic Surgery, Schulich School of 
Medicine & Dentistry, The University of Western Ontario 
2019 - present Assistant Professor, Department of Oncology, Division of Surgical Oncology, Schulich School 
of Medicine & Dentistry, The University of Western Ontario 
Clinical Appointments 
2019 - present Thoracic Surgeon, London Health Sciences Centre, Department of Surgery, Division of 
Thoracic Surgery 
POSITIONS HELD & LEADERSHIP EXPERIENCE
Academic Positions
2020 - present Program Director - Thoracic Surgery, Western University, Schulich School of Medicine & 
Dentistry, Surgery, London, Ontario, Canada 
2019 - present Surgery Clerkship Specialty Director - Thoracic Surgery, Western University, Schulich School 
of Medicine & Dentistry, Surgery, London, Ontario, Canada 
2019 - present Simulation Director - Thoracic Surgery, Western University, Schulich School of Medicine & 
Dentistry, Surgery, London, Ontario, Canada 
2019 - 2020 Assistant Program Director - Thoracic Surgery, Western University, Schulich School of 
Medicine & Dentistry, Surgery, London, Ontario, Canada 
2017 - present Western Surgical Bootcamp instructor  Chest tube insertion 
2017 - 2018 Chief resident  Thoracic Surgery, London Health Science Centre 
2015 - 2016 Resident-representative of Fleurimont Hospital for General, Pediatric, Vascular and Thoracic 
Surgery 
SERVICE AND ADMINISTRATION
Professional Affiliations and Activities 
Professional Associations 
2017 - 2030 Member, Canadian Association of Thoracic Surgeons 
2017 - 2030 Member, Society of Thoracic Surgeons 
2017 - 2030 Member, Royal College of Physician and Surgeons of Canada 
RESEARCH AND SCHOLARLY ACTIVITIES
Research Endeavours 
2020 Education strategies to teach chest tube insertion - A systematic review, What are the 
existing methods in literature for teaching chest tube insertion to the undergraduate and 
post-graduate medical learners and surgical residents 
2019 - 2020 Pleurodesis using hypertonic glucose administration to treat post-operative air leaks 
following lung resection surgery - A systematic review, Systematic review on the intrapleural 




2020 Dec - 2021 Dec 
Role: Principal Investigator 
Title: Extended Reality Applications in Surgical 
Education 
Co-Investigators: Ge Shi, Richard Malthaner, 
Michael Ott, Elvis Chen, Terry Peters 
Funding Source: Western University DoS 
Resident Research Grant 
Principal Investigator: Mehdi Qiabi 
Grant Total: $5,000
Industry Grant: N 
Past Grants 
2018 Dec - 2019 Nov
Role: Co-Investigator 
Title: Pleurodesis Using Glucose administration 
to treat post-operative air leaks following lung 
resection surgery (PLUG): Phase 1 and Phase 2 
trials ($10,000) 
Co-Investigators: Qiabi M, Inculet R, Fortin D 
Funding Source: Western University DoS 
Internal Research Fund 
Principal Investigator: Malthaner R 
Grant Total: $10,000 
Industry Grant: N 
Other Professional Activities 
Education - Graduate 
2019 - 2020 Facilitator, Thoracic Surgery Crises Simulation, Western University, Research Project, In situ 
simulation sessions for Thoracic Surgery fellows, senior residents in Anesthesia and Cardiac 
Surgery and nurses, Collaborators: Dr Richard Malthaner 
PUBLICATIONS
Peer Reviewed Publications 
Journal Article 
Published 
1. Dwyer CD, Qiabi M, Fortin D, Inculet RI, Nichols AC, MacNeil SD, Malthaner R, Yoo J, Fung K. Idiopathic
Subglottic Stenosis: An Institutional Review of Outcomes With a Multimodality Surgical Approach.
Otolaryngol Head Neck Surg. Online ahead of print. 2020 Oct 13: 194599820966978, Coauthor, DOI:
10.1177/0194599820966978.
Submitted 
1. McDonald A, Qiabi M, Leeper R, Fortin D, Inculet R, Malthaner R. Thoracic Surgery Crisis Simulation During
the COVID-19 Pandemic. Canadian Journal of Surgery, 2020 Sep 25, Coauthor
2. Shi G, Calvin C, Taheri K, Aziz R, Lai M, Duan N, Rothman Z, Darras K, Schlachta C, Malthaner R, Qiabi M,
Pennefather P, Krebs C, Blair G. Extended Reality Applications in Surgery. 2020 May 25, Collaborator
3. Qiabi M, Inculet R, DaSilva W, Bierer J, Malthaner A, Warner A, Fortin D, Malthaner R. Robotic-Assisted
Giant Paraesophageal Hernia Repair Compared to Traditional Approaches. Annals of Thoracic Surgery,
2020 Feb 17, Principal Author
4. Qiabi M, Dwyer C, Yoo J, Fortin D, Malthaner R, Fung K, Inculet R. Resection of Upper Tracheal Stenoses
With Laryngeal Mask Airway Ventilation: Long Term Results. Annals of Thoracic Surgery, 2019 Jul 15,
Principal Author
Book Chapter / Review Article 
Published 
1. Butter A, Rieder S, Qiabi M





1. Alexandra McDonald. Thoracic surgery crisis simulation during the COVID-19 pandemic. Canadian
Conference for the Advancement of Surgical Education: Abstracts. Can J Surg; 2020. p. S61-S78. Coauthor.
DOI: 10.1503/cjs.021920
Abstracts Presented 
1. Qiabi M, Hetu J, Comeau E. Prevalence of staging laparoscopy among eligible gastric cancer patients at the
CHUS: 10 years experience. 2016, CHUS Surgical Department annual research day, Sherbrooke, Quebec,
Canada, Presenter
Posters Presented
1. Qiabi M, Dwyer C, Yoo J, Fortin D, Malthaner RA, Fung K, Inculet RI. Subglottic and Cervical Tracheal
Stenoses With Laryngeal Mask Airway Ventilation: Long Term Surgical Results. 2019, 55th Annual Meeting




1. Presenter, Robotic-Assisted Giant Paraesophageal Hernia Repair Compared to Traditional Approaches.
56th Annual Meeting of the Society of Thoracic Surgeons (STS)s, Presenters: Qiabi M, Inculet R, DaSilva W,





2019 - 2020 Medical and Educational Director, Thoracic Surgery Clerkship Virtual Curriculum created at 
the request of the Western Surgery Clerkship Director (Dr A Butter) in response to the Global 
Pandemic. Undergraduate, Thoracic Surgery Clerkship Virtual Curriculum, Western 
University, Schulich School of Medicine & Dentistry, Department of Surgery, Division of 
Thoracic Surgery, Hours: 40, London, Ontario, Canada 
Postgraduate 
2019 - 2020 Course Director, Development of a Thoracic Surgery Difficult Surgical Exposure Course (TS-
DISEC) in collaboration with Dr Tyler Beveridge (Department of Anatomy & Cell Biology), 
inaugural session was held Feb 25, 2020. Postgraduate, TS-DISEC, Western University, 
Schulich School of Medicine & Dentistry, Department of Surgery, Division of Thoracic 
Surgery, Hours: 12, 2, London, Ontario, Canada 
2019 - 2020 Medical and Educational Director, Renewed and revamped education curriculum for Thoracic 
Surgery fellows with updated monthly mock examinations. Postgraduate, Western Thoracic 
Surgery Fellowship renewed educational curriculum - practice written examinations, 
Western University, Schulich School of Medicine & Dentistry, Department of Surgery, 
Division of Thoracic Surgery, Hours: 60, 2, London, Ontario, Canada 
OTHER ACTIVITIES
Areas of Interest 
Clinical 
Endoscopy 





Simulation in Thoracic Surgery 
Teaching 
Curriculum design 
Video-based assessments 
